<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        8-883-16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FLAGYL 250MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METRONIDAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        10.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SANOFI-AVENTIS, S.A" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SANOFI-AVENTIS, S.A
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            sanofi-aventis
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        P01AB01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group<br />Flagyl is an antibacterial and antiparasitic antibiotic belonging to the 5-nitroimidazole group of medicines.<br />Therapeutic indications<br />It is used to treat certain infections caused by bacteria or parasites that are sensitive to Flagyl.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Contraindications<br />Do not take Flagyl 250 mg:<br />- if you are allergic to metronidazole, to any medicine in the imidazole group (the group of antibiotics that includes metronidazole) or to any other ingredient of this medicine listed in Section 6,<br />- if you are allergic (hypersensitive) to wheat, as this medicine contains wheat starch (gluten),<br />- if the patient is a child under 6 years of age (see &ldquo;Warnings and precautions&rdquo;).<br />Appropriate precautions for use; special warnings<br />Warnings and precautions<br />Before taking Flagyl 250 mg, tell your doctor if:<br />- you have severe, chronic or progressive<br />nervous disorders,<br />- you have psychiatric disorders,<br />- you have blood disorders,<br />- you have ever had meningitis under metronidazole<br />treatment.<br />Tell your doctor immediately if any of the following problems occur during treatment with Flagyl 250 mg:<br />From the first dose, there is a risk of severe and sudden allergic reaction (anaphylactic shock, angioedema) possibly causing the following symptoms: tight chest, dizziness, nausea or fainting, or dizziness when standing up (see &ldquo;Possible side effects&rdquo;). If these symptoms occur, stop taking this medicine because your life might be in danger and immediately contact a doctor.<br />If, at the start of treatment, you experience redness all over the body and pustules, accompanied by fever, a serious reaction known as acute generalized exanthematous pustulosis should be suspected (see &ldquo;Possible side effects&rdquo;); inform your doctor immediately as treatment must be stopped. Any further administration of metronidazole alone or in combination with another active substance in the same medicine is contraindicated if such a reaction occurs.<br />If you find it difficult to coordinate voluntary movements or if you feel dizzy or confused, you should stop taking the medicine and see a doctor.<br />From the very first doses of treatment, your behavior may alter and put you at risk, especially if you have had psychiatric problems in the past (see &ldquo;Possible side effects&rdquo;). If this happens, you should stop taking the medicine and see a doctor.<br />During long-term treatment, you should watch out for any signs of nervous disorders such as tingling, difficulty coordinating movements, dizziness or seizures. If these occur, it is important to inform your doctor.</p><p>If you have had blood disorders in the past, or received high-dose and/or long-term treatment, your doctor may prescribe regular blood tests to check your complete blood count.<br />Inform the doctor or analysis laboratory that you are taking this medicine if you have to have a medical laboratory test: taking metronidazole may interfere with some laboratory test results (test for treponema), by triggering a false positive result for a test (Nelson test).<br />Children<br />The administration of tablets is contraindicated in children under 6 years of age due to the risk of choking. More suitable dosage forms and strengths of this antibiotic exist for young children.<br />Talk to your doctor or pharmacist before taking Flagyl 250 mg.<br />Other medicines and Flagyl 250 mg<br />Tell your doctor or pharmacist if you are taking, have recently taken or may take any other medicines.<br />Tell your doctor if you are taking:<br />- medicines containing alcohol because of the risk of side effects such as redness of the face, feeling hot, vomiting and increased heart rate,<br />- busulfan (recommended for the treatment of certain types of blood disorders and for the preparation of a bone marrow transplant),<br />- disulfiram (used to prevent relapse in alcohol-dependent patients).<br />Flagyl 250 mg with alcohol<br />Drinking alcoholic beverages should be avoided during treatment because of the risk of side effects such as redness of the face, feeling hot, vomiting and increased heart rate.<br />Pregnancy and breast-feeding<br />If necessary, this medicine may be taken during pregnancy. However, you must always ask your doctor or pharmacist for advice before taking it.<br />You should avoid breast-feeding while taking this medicine.<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br />Driving and using machines<br />You should be aware, particularly if you drive or use machines, that there is a risk of dizziness, confusion, hallucinations, seizures and vision disorders associated with this medicine.<br />Important information about some of the ingredients of Flagyl 250 mg<br />You may take this medicine if you have celiac disease. Wheat starch can contain gluten, but only traces, and is therefore considered safe for patients with celiac disease.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dosage<br />This medicine is for adults and children from 6 years of age only. More suitable dosage forms exist for children under 6 years of age.<br />The dosage depends on your age and the illness being treated.<br />As an indication, the usual dose is:<br />- Adults: 0.50 g/day to 1.5 g/day,<br />- Children: 375 mg/day to 20-40 mg/kg/day.<br />In some cases, it is essential that your partner be treated, whether or not he/she has any clinical signs.<br />IN ALL CASES, FOLLOW YOUR DOCTOR&rsquo;S PRESCRIPTION.<br />How Flagyl should be taken<br />Oral use.<br />Swallow the tablets with a glass of water.<br />How often Flagyl should be taken<br />2 to 3 times a day depending on why you are taking this medicine.<br />How long Flagyl should be used for<br />In order to be effective, this antibiotic must be used regularly at the prescribed doses and for as long as your doctor advises.<br />If your fever or any other symptom disappears, it does not mean that you are cured.<br />If you feel tired, this is not due to the antibiotic treatment but to the infection itself. Reducing or suspending treatment would have no effect on this feeling and would only delay your recovery.<br />Particular cases: treatment of giardiasis (infection caused by a parasite) should last 5 days, treatment of amebiasis (infection caused by a parasite) and some types of vaginosis (infection of the vagina), 7 days and treatment of trichomoniasis (infection caused by a parasite), consists of a single dose.<br />If you take more Flagyl 250 mg than you should<br />If you are vomiting, have difficulty coordinating your movements or are disorientated, consult your doctor. Your doctor may decide to prescribe medication.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Flagyl 250 mg can cause side effects, although not everybody gets them.<br />Digestive disturbances:<br />- digestive disorders that are not serious, such as stomach pains, nausea, vomiting, diarrhea,<br />- inflammation of the tongue and dry mouth, inflammation of the mouth, taste disorders, loss of appetite,<br />- pancreatitis (inflammation of the pancreas), which is reversible after stopping treatment.<br />Effects on the skin and mucous membranes:<br />- hot flushes with redness of the face, itching, skin rashes sometimes accompanied by fever,<br />- hives (skin rash similar to nettle rash), sudden allergic swelling of the face and neck (angio-edema), allergic shock which could be life-threatening (see &ldquo;What you need to know before you take Flagyl 250 mg&rdquo;),<br />- very rare cases of redness spreading to the whole body with pustules, accompanied by fever (acute generalized exanthematous pustulosis) (see &ldquo;What you need to know before you take Flagyl 250 mg&rdquo;).</p><p>Nervous system disorders:<br />- headache,<br />- nerve impairment in the limbs,<br />- seizures, dizziness,<br />- confusion,<br />- neurological disorders which can include consciousness disorders, behavioral disorders, difficulty coordinating movements, pronunciation disorders, gait disorders, involuntary eye movements, shakiness. These disorders are generally reversible on treatment discontinuation.<br />- non-bacterial meningitis.<br />Mental disorders:<br />- hallucinations,<br />- personality disorders (paranoia, delusion) possibly with suicidal ideas or attempts (see &ldquo;What you need to know before you take Flagyl 250 mg&rdquo;),<br />- depressive tendencies.<br />Vision disorders:<br />- temporary vision disorders such as blurred vision, double vision, short-sightedness, decreased vision, changes in color vision,<br />- optic nerve damage/inflammation.<br />Blood disorders:<br />- abnormally low platelet counts, abnormally low or major drop in the number of certain white blood cells (neutrophils).<br />Liver effects:<br />- abnormal liver function test results which are reversible, hepatitis (liver disease) possibly caused by biliary tract obstruction (sometimes with jaundice).<br />Other effects:<br />- reddish-brown colored urine caused by the medicine.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.<br />By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>KEEP OUT OF THE SIGHT AND REACH OF CHILDREN.<br />Do not use Flagyl 250 mg after the expiry date which is stated on the outer packaging.<br />Store below 30 &deg;C, protected from light.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Flagyl 250 mg film-coated tablets contain<br />The active substance is:<br />Metronidazole &hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;.........&hellip;&hellip;250 mg<br />for one film-coated tablet.</p><p>Wheat starch, povidone K30, magnesium stearate, hypromellose, macrogol 20000</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                contents of the pack
This medicine is supplied as film-coated tablets, in boxes of 20.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong><br />sanofi-aventis France<br />1-13, boulevard Romain Rolland<br />75014 Paris - France</p><p><strong>Manufacturer</strong><br />sanofi-aventis S.A.<br />Ctra. C.35 &ndash;La Battloria a Hostalric, Km 63,09<br />17404 Riells i Viabrea (Gerona)<br />Spain</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April 2014
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>المجموعة الدوائیّة العلاجیّة<br />- فلاجیل ھو مضاد حیوي مضاد للبكتیریا ومضاد للطفیلیاّت ینتمي إلى مجموعة الأدویة 5<br />نیترویمیدازول.<br />دواعي الاستعمال العلاجیّة<br />یسُتعمل ھذا الدواء لعلاج بعض حالات الخمج التي تسبّبھا بكتیریا أو طفیلیاّت تتأثرّ بفلاجیل</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع الاستعمال<br />لا تأخذ فلاجیل 250 ملغ:<br />- إذا كنت تعاني من حساسیّة ضدّ المترونیدازول أو ضدّ أيّ دواء من مجموعة الإیمیدازول<br />(مجموعة المضادات الحیویّة التي تتضمّن المترونیدازول)، أو ضدّ أيّ من المركّبات<br />. الأخرى في ھذا الدواء وھي مذكورة في القسم 6<br />- إذا كنت تعاني من فرط حساسیّة ضدّ القمح لأنّ ھذا الدواء یحتوي على نشا القمح (الغلوتن)،<br />- إذا كان المریض طفلاً ما دون السادسة من العمر (راجع فقرة &quot;تحذیرات ومحاذیر&quot;).<br />محاذیر مناسبة للاستعمال؛ تحذیرات خاصة<br />تحذیرات ومحاذیر<br />قبل أخذ فلاجیل 250 ملغ، أعلم طبیبك إذا:<br />- كنت تعاني من اضطرابات عصبیّة حادة أو مزمنة أو تصاعدیّة،<br />- كنت تعاني من اضطرابات نفسیّة،<br />- كنت تعاني من اضطرابات في الدم،<br />- أصُبت یومًا بالتھاب السحایا في خلال فترة علاج بالمترونیدازول.<br />أعلم طبیبك على الفور إذا واجھت أیًّا من المشاكل التالیة في خلال مدّة العلاج بفلاجیل 250 ملغ:<br />م ن الجرع ة الأولى ، تواج ھ خط ر التعرّض لارتكاس تحسس ي حا د ومفاج ئ (صدم ة تأقیّة ، خزب<br />وعائي) قد یسبّب العوارض التالیة: ضیق في الصّدر، دوار، غثیان أو إغماء، أو دوار عند الوقوف<br />(راجع قسم &quot;التأثیرات الجانبیّة المحتملة&quot;). في حال حصول ھذه العوارض، توقّف ع ن أخ ذ ھذا<br />الدواء لأنّ حیاتك قد تكون في خطر واتصل بالطبیب على الفور.<br />في حال أصبت في بدایة العلاج باحمرار أو بانتشار بثور على جسمك كلّھ، مع حمى، یجب الشكّ<br />بإصابتك بارتكاس خطیر یُعرف بالبُثار الطفحي المعمّم (راجع قسم &quot;التأثیرات الجانبیّة المحتملة&quot;)؛<br />أعلم طبیبك على الفور لأنّھ یجب إیقاف العلاج. وفي حال حصول ھذا الارتكاس، یُمنع أيّ استعمال<br />آخر للمترونیدازول لوحده أو بالاشتراك مع مادة فاعلة أخرى في الدواء ذاتھ.<br />إذ ا وجدت صعوبة في تنسیق الحركات الإرادیّ ة أ و إذا شعرت بالارتباك أ و بالتشوّش، یجب علیك<br />التوق فّ عن أخذ الدواء ومراجعة الطبیب.<br />من الجرعات الأولى، قد یتغیّر سلوكك ویعرّضك للخطر، بخاصة إذا عانیت في السابق من مشاكل<br />نفسیّة (راجع قسم &quot;التأثیرات الجانبیّة المحتملة&quot;). في ھذه الحالة، یجب علیك التوقّف عن أخذ الدواء<br />ومراجعة الطبیب.<br />في خلال العلاج الطویل الأمد، یجب علیك الانتباه لأيّ عوارض اضطرابات عصبیّة مثل الوخز<br />وصعوبة تنسیق الحركات والدوار ونوبات الصرع. في ھذه الحالات، من المھمّ أن تعُلم طبیبك.<br />في حال عانیت في السابق من اضطرابات في الدم أو تلقّیت علاجًا عالي الجرعة و/أو طویل الأمد،<br />قد یصف لك طبیبك فحوصات دم عادیّة للتحقق من تعدادك الدموي الكامل.<br />أعلم الطبیب أو مختبر التحلیل أنّك تأخذ ھذا الدواء إذا كان علیك الخضوع لفحص مخبريّ طبي،<br />فأخذ المترونیدازول قد یتداخل مع بعض نتائج الفحوصات المخبریّة (فحص اللولبیّة)، عبر إطلاق<br />نتیجة إیجابیّة خاطئة لفحص معیّن (فحص نلسون).<br />الأطفال<br />یُمنع إعطاء الأقراص للأطفا ل ما دون السادسة من العمر بسبب خطر الاختناق . توجد أشكال<br />وعیارات من المضاد الحیوي ھذا خاصة بالأطفال الصغار.<br />تحدّث إلى الطبیب أو الصیدلي قبل أخذ فلاجیل 250 ملغ.<br />أدویة أخرى وفلاجیل 250 ملغ<br />أعلم الطبیب أو الصیدلي إذا كنت تأخذ حالیًا أو أخذت مؤخّرًا أو قد تكون تأخذ أيّ أدویة أخرى.<br />أعلم الطبیب إذا كنت تأخذ:<br />- أدویة تحتوي على الكحول بسبب خطر التعرّض لتأثیرات جانبیّة مثل احمرار الوجھ والشعور<br />بالحرّ والتقیّؤ وزیادة سرعة القلب،<br />- البوسولفان (الذي یوصف لعلاج بعض أنواع اضطرابات الدم ولتحضیر زرع نقيّ العظم)،<br />- الدیسولفیرام (المستعمل للحؤول دون الانتكاس لدى المرضى المعتمدین على الكحول).<br />فلاجیل 250 ملغ مع الكحول<br />یجب تفاد ي استھلا ك الكحو ل ف ي خلا ل فتر ة العلا ج بسبب خط ر التعرّض لتأثیرات جانبیّ ة مثل<br />احمرار الوجھ والشعور بالحرّ والتقیّؤ وزیادة سرعة القلب.<br />الحمل والإرضاع<br />عند الضرورة، یمكن أخذ ھذا الدواء في خلال فترة الحمل. ولكن یجب علیك دائمًا استشارة الطبیب<br />أو الصیدلي قبل أخذه.<br />علیك تفادي الإرضاع في خلال فترة العلاج بھذا الدواء.<br />إذا كنتِ حاملاً أو مرضعة أو كنت تعتقدین نفسك حاملاً أو كنتِ تنوین الحمل، یجب علیك دائمًا<br />استشارة الطبیب أو الصیدلي قبل أخذ ھذا الدواء.<br />قیادة السیّارات واستعمال الآلات<br />یجب علیك أن تدرك، بخاصة إذا كنت تقود أو تستعمل آلات، وجود خطر تعرّضك لدوار وتشوّش<br />ذھني وھلوسات ونوبات واضطرابات في النظر بسبب استعمال ھذا الدواء.<br />معلومات مھمّة حول بعض مركّبات فلاجیل 250 ملغ<br />یمكنك أخذ ھذا الدواء إذا كنت تعاني من التغوّط الشحمي التلقائي. یمكن أن یحتوي نشا القمح على<br />الغلوتن ولكن بكمیّة ضئیلة جدًّا وبالتالي یُعتبر آمنًا للمرضى المصابین بالتغوّط الشحمي التلقائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>مقدار الجرعة<br />ھذا الدواء ھو فقط للبالغین وللأطفا ل ف ي السادس ة م ن العم ر وم ا فوق . تتواف ر للأطفا ل م ا دون<br />السادسة من العمر أشكال دوائیّة تناسبھم أكثر.<br />یتوقّف مقدار الجرعة على عمرك وعلى المرض المعالج.<br />على سبیل الإشارة، یبلغ مقدار الجرعة العادیّة:<br />- لدى البالغین: 0.50 غ/الیوم إلى 1.5 غ/الیوم،<br />40 ملغ/كلغ/الیوم. - - لدى الأطفال: 375 ملغ/الیوم إلى 20<br />في بعض الحالات، من الضروري أن یُعالج شریكك/شریكتك، أكان لدیھ/لدیھا إشارات سریریّة أو<br />لا.<br />في مطلق الأحوال، تقیّد بوصفة الطبیب.<br />كیف یجب أخذ فلاجیل<br />عن طریق الفم.<br />إبلع الأقراص مع كوب من الماء.<br />ما ھو عدد مرّات استعمال فلاجیل<br />من 2 إلى 3 مرّات في الیوم حسب السبب الذي تأخذ من أجلھ ھذا الدواء.<br />ما ھي مدّة العلاج بفلاجیل<br />لكي یكون المضاد الحیوي ھذا فعّالاً، یجب استعمالھ بانتظام حسب الجرعات الموصوفة وللمدّة التي<br />یحدّدھا الطبیب.<br />لا یعني اختفاء الحرارة أو أيّ عارض آخر أنّك شفیت. فأيّ شعور بالتعب لا یعود إلى العلاج<br />بالمضاد الحیوي ولكن إلى حالة الخمج نفسھا. لذلك لن یؤثّر تخفیض الجرعة أو إیقاف العلاج على<br />ھذا الشعور وسوف یؤخّر شفاءك.<br />حالات خاصة: یجب أن یدوم علاج داء الجیاردیّات (حالة خمج یسبّبھا طفیليّ) لخمسة أیّام، وعلاج<br />داء الأمیبة (حالة خمج یسبّبھا طفیليّ) وبعض أنواع التھاب المھبل 7 أیّام وعلاج داء المشعّرات<br />(حالة خمج بسبّبھا طفیليّ) یتمّ بجرعة وحیدة.<br />إذا أخذت جرعة مفرطة من فلاجیل 250 ملغ<br />إذا كنت تتقیأّ أو تواجھ صعوبة في تنسیق حركاتك أو تشعر بالتھیان، استشر الطبیب الذي قد یقرّر<br />وصف دواء لك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل الأدویة كلّھا، قد یسبّب فلاجیل 250 ملغ تأثیرات جانبیّة لا تصُیب المرضى كلّھم.<br />إضطرابات ھضمیّة:<br />- اضطرابات ھضمیّة لیست خطیرة، مثل أوجاع المعدة والغثیان والتقیّؤ والإسھال،<br />- إلتھاب اللسان وجفاف الفم، التھاب الفم، اضطرابات في حاسة الذوق، فقدان الشھیّة،<br />- التھاب البنكریاس لكنّھ یزول بعد إیقاف العلاج.<br />تأثیرات على الجلد والأغشیة المخاطیّة:<br />- ھبو مع احمرار الوجھ، حكّة، طفح جلدي مع حرارة أحیاناً،<br />- شرى (طفح جلدي شبی ھ بطفح القرّاص) ، تورّم إرجيّ مفاجئ في الوجھ والعنق (خزب وعائي)<br />وصدمة إرجیّة یمكن أن تسبّب الوفاة (راجع قسم &quot;ما ھي المعلومات التي یجب علیك معرفتھا قبل<br />أن تأخذ فلاجیل 250 ملغ&quot;)،<br />- حالات نادرة جدًا من الاحمرار الذي ینتشر على جسمك كلّھ مع بثور ومع حمى (البُثار الطفحي<br />المعمّم الحاد) (راجع قسم &quot;ما ھي المعلومات التي یجب علیك معرفتھا قبل أن تأخذ فلاجیل 250<br />ملغ&quot;).<br />إضطرابات الجھاز العصبي:<br />- صداع،<br />- ضعف في أعصاب الأطراف،<br />- نوبات، دوار،<br />- تشوّش ذھني،<br />- اضطرابات عصبیةّ یمكن أن تتضمّن اضطرابات في الوعي واضطرابات في السلوك وصعوبة<br />ف ي تنسی ق الحركات واضطرابات ف ي اللف ظ واضطرابات ف ي المشی ة وحركات غی ر إرادیّ ة في<br />العینین ورجفة. عادة ما تزول ھذه الاضطرابات عند إیقاف العلاج.<br />- التھاب السحایا غیر البكتیري.<br />اضطرابات عقلیّة:<br />- ھلوسات،<br />- اضطرابات في الشخصیّة (جنون العظمة، وھام) یُحتمل أن تترافق مع أفكار انتحاریّة<br />ومحاولات انتحار (راجع قسم &quot;ما ھي المعلومات التي یجب علیك معرفتھا قبل أن تأخذ فلاجیل<br />250 ملغ&quot;)،<br />- میول اكتئابیةّ.<br />اضطرابات في الرؤیة:<br />- اضطرابات مؤقتة في الرؤیة مثل عدم وضوح الرؤیة وازدواج الرؤیة وقصر النظر وضعف<br />النظر وتغییرات في رؤیة الألوان،<br />- تلف / التھاب العصب البصري.<br />اضطرابات الدم:<br />- انخفاض غیر طبیعي في تعداد صفیحات الدم، وانخفاض غیر طبیعي أو ھبوط كبیر في عدد بعض<br />خلایا الدم البیض (العدلات).<br />تأثیرات على الكبد:<br />- حالات نادرة جدً ا من عد م سویّ ة الوظیف ة الكبدیّ ة ولكنّھا تزول ومن التھاب الكب د بسبب انسداد<br />القناة الصفراویّة (مع یرقان أحیاناً).<br />- تأثیرات أخرى:<br />- تلوّن البول بالبنّي المائل إلى الاحمرار بسبب الدواء.<br />الإفادة عن التأثیرات الجانبیةّ<br />إذا أصبت بأيّ تأثیرات جانبیةّ، أعلم الطبیب أو الصیدلي ویتضمّن ذلك أيّ تأثیرات جانبیةّ غیر<br />مذكورة في ھذه النشرة.<br />بالإفادة عن التأثیرات الجانبیّة، یمكنك المساعدة على تزوید المزید من المعلومات حول سلامة ھذا<br />الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>إحفظ الدواء بعیدًا عن نظر الأطفال ومتناولھم.<br />لا تستعمل فلاجیل 250 ملغ بعد انقضاء تاریخ الصلاحیّة المدوّن على الغلاف الخارجيّ.<br />إحفظ الدواء في حرارة ما دون 30 درجة مئویّة بعیدًا عن النور.<br />لا ترمِ أيّ أدویة في المیاه المبتذلة أو مع النفایات المنزلیّة. إسأل الصیدليّ عن كیفیّة التخلّص من<br />الأدویة التي لم تعد تحتاج إلیھا. فمن شأن ھذه الإجراءات حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ماذا یحتوي فلاجیل 250 ملغ، أقراص مغلفّة بطبقة رقیقة<br />المادة الفاعلة ھي:<br />مترونیدازول....................................................................................... 250 ملغ<br />للقرص الواحد المغلّف بطبقة رقیقة.<br />المركّبات الأخرى ھي:<br />. نشا القمح، بوفیدون كاي 30 ، ستیارات المغنیزیوم، ھبرومیلوز، ماكروغول 20000</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            یأتي ھذا الدواء على شكل أقراص مغلفّة بطبقة رقیقة في علب من 20
قد لا تكون أحجام العلب كلّھا مسوّقة في بلدك.
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>الشركة حاملة رخصة التسویق والشركة المشغّلة</strong><br />sanofi-aventis France<br />1-13, boulevard Romain Rolland<br />75014 Paris, France</p><p><br /><strong>الشركة المصنّعة</strong><br />Sanofi-aventis S.A.<br />Ctra. C-35-La Battloria a Hostalric, Km 63,09<br />17404 Riells i Viabrea (Gerona)<br />Spain</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نیسان 2014
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                FLAGYL 250 mg film-coated tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                metronidazole ........................................................................................................................... 250,00 mg
Excipients : maize starch, povidone K30, magnesium stearate, hypromellose, macrogol 20000.
For one tablet.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The indications are based. on the antiparasitic and antibacterial activity and the pharmacokinetic characteristics of metronidazole, taking into consideration both the clinical studies carried out with the medicinal product and its place in the range of anti-infectious drugs currently available.<br />It is indicated in the treatment of infections caused by micro-organisms identified as susceptible:<br />- amebiosis<br />- genitourinary trichomoniasis<br />- non-specific vaginitis<br />- lambliasis<br />- curative treatment of medical-surgical infections caused by susceptible anaerobic micro-organisms<br />- replacement for curative IV treatment of infections caused by susceptible anaerobic<br />micro-organisms<br />It is important to take into account official recommendations concerning the appropriate use<br />of antibacterial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>* Amebiosis<br />Adults<br />1,50 g/day in 3 intakes<br />Children<br />30 mg to 40 mg/kg/day in 3 intakes<br />In the event of amebic liver abscess, drainage or aspiration of pus should be performed in conjunction with metronidazole therapy. Treatment duration is 7 consecutive days.<br />* Trichomoniasis<br />- in women (trichomonas urethritis and vaginitis), a 10-day treatment period associating:<br /> 0.50 g/day in two oral intakes<br /> 1 pessary/day<br />The sexual partner should be treated concomitantly, whether presenting with clinical signs of<br />trichomonas vaginalis infection or not, even if laboratory test results are negative.<br />- in men (trichomonas urethritis):<br /> 0.50 g/day in two oral intakes for 10 days<br />In very rare cases, it may be necessary to increase the daily dose to 0.750 g or l g.</p><p>* Lambliasis<br />Adults<br />0.750 g to 1 g/day for 5 consecutive days<br />Children<br />6 to 10 years: 375 mg/day<br />10 to 15 years: 500 mg/day<br />* Non-specific vaginitis<br />500 mg twice daily for 7 days.<br />The partner should be treated concomitantly.<br />* Treatment of infections caused by susceptible anaerobic micro-organisms<br />(first line treatment or replacement treatment)<br />Adults<br />l g to 1.5 g/day<br />Children<br />20 mg to 30 mg/kg/day</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                This drug should never be used in the followings events:
- Hypersensitivity to imidazoles
- Hypersensitivity or intolerance to gluten, due to the presence of wheat starch (gluten).
- In children under 6 years of age, due to the pharmaceutical form
It is generally inadvisable to use this medicine in combination with disulfiram or alcohol (see section 4.5 Interactions with other medicines and other forms of interaction)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Warnings:<br />- Avoid alcoholic drinks (antabuse effect) (see section 4.5 Interactions with other medicines and other forms of interaction)<br />- Stop treatment if ataxia, vertigo or mental confusion occur.<br />- It is important to bear in mind the risk of worsening of neurological status in patients with severe, chronic or active central and peripheral neurological disorders.<br />Precautions for use<br />- There is not thought to be any risk of carcinigenicity in man although the product proved to be carcinogenic in a certain species of mouse. However, this was not the case in the rat or the hamster<br />- In case of history of hematological disorder as well as during treatment at high doses and/or for long periods; it is recommended to regularly monitor white blood cell count.<br />- In the event of leucopenia, the opportunity to prolong the treatment depends on the seriousness of the infection.<br />- In the event of prolonged treatment, control manifestation of signs leading to undesirable effects such as central and peripheral neuropathies (paresthesia, ataxia, vertigo or convulsive crisis)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Inadvisable combinations:<br />+ Alcohol: antabuse effect (hotness, redness, vomiting, tachycardia).<br />Avoid alcoholic drinks and alcohol-containing medicines.<br />+ Disulfiram: attacks of delirium, confusional state.<br />Combinations requiring precautions:<br />+ Oral anticoagulants: increased effect of oral anticoagulants and risk of bleeding via<br />decrease in their hepatic metabolism.<br />More frequent checks of prothrombin rate and monitoring of INR.</p><p>Adjust the dosage of oral anticoagulants during treatment with metronidazole and for a<br />week after it is stopped.<br />Combination needing to be taken into account:<br />- fluorouracil: increased toxicity of fluorouracil via decreased clearance.<br />Specific problems concerning the INR<br />Many case of activity increase in oral anticoagulant therapy have been reported with patients<br />treated with antibiotics. Infectious and inflammatory states and general health states might be<br />risk factors. It is difficult to identify between the infectious pathology and its treatment in the<br />incidence on the INR. However, some antibiotic series are more concerned. This concerns<br />especially fluoroquinolones, macrolides, cyclines, cotrimoxazole and some of cephalosporins.<br />Interactions with paraclinical tests<br />Metronidazole may immobilize treponemes, giving a false positive TPI test.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Animal studies have evidenced no teratogenic effects. In the absence of teratogenic effects in animals, malformative effects are not expected in man.<br />To the present date, substances responsible for malformation in man have been teratogenic in animals during well-conducted studies in two species.<br />From a clinical point of view, no particular or fetotoxic effect has been shown on exposed pregnancies after analysis.<br />However, further epidemiological studies are necessary to confirm the absence of risk.<br />Metronidazole can therefore be prescribed during pregnancy if&#39; required.<br />Breast-feeding<br />As metronidazole pass into maternal milk, Flagyl 250 mg film-coated tablet should not be used during breast-feeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Attention is drawn, particularly that of drivers and machinery operators, to the risks of<br />vertigo, confusion, hallucinations or convulsions associated with the use of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gastrointestinal system:<br />-innocuous digestive upsets: (epigastric cramps, nausea, vomiting, diarrhea)<br />-glossitis with feelings of dry mouth, stomatitis, metallic taste in mouth, anorexia,<br />-extremely rarely reversible cases of pancreatitis when the treatment is stopped.<br />Skin and appendices<br />-congestive flushes, pruritus, cutaneous sometimes febrile manifestations;<br />-urticaria, Quincke&#39;s oedema, rarely anaphylactic shock.<br />Central and peripheral nervous system<br />-headaches<br />-sensory peripheral neuropathies<br />-convulsions, vertigo, ataxia<br />Psychiatric troubles<br />-Confusion, hallucinations<br />Blood lineage<br />-Very rare cases of neutropenia, agranulocytosis and thrombopenia<br />Hepatic symptoms<br />-Very rare case of reversible anomalies of hepatic tests and cholestatic hepatitis.</p><p>Miscellaneous<br />-Reddish-brown coloration of the urine may be seen, due to the presence of water-soluble<br />pigments derived from metabolization of the medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Some administration of unique dose up to 12 g have been reported during suicide attempts<br />and fortuitous overdosage.<br />Symptoms were limited to vomiting, ataxia, light disorientation. There is no specific antidote<br />for overdosage of metronidazole. In case of massive overdosage, the treatment is<br />symptomatic.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ANTIBIOTIC, ANTIBACTERIAL, ANTIPARASITIC belonging to the nitro-5- imidazole group<br />(J: Anti-infectious agents, other imidazole-derived antibacterials, P: antiprotozoal<br />agents, medicinal products to treat amebiasis and other parasitic diseases -<br />metronidazole derivatives<br />Code ATC: J0lXD0l-P0lAB0l</p><p>Critical concentrations differentiate sensitive strains from those of moderate sensitivity, and<br />strains of moderate sensitivity from resistant ones:<br />S&le; 4 mg/l and R&gt; 4 mg/l<br />For certain species, the prevalence of acquired resistance may vary as a function of place and<br />time. It is useful, therefore, to have information on the prevalence of local resistance,<br />particularly when treating severe infections. These data can only provide an indication as to<br />the sensitivity of a strain of bacteria to this antibiotic.<br />When the variability of the prevalence of resistance for a given species of bacteria is known in<br />France, it is indicated in the table below:</p><p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RESRXhpZgAATU0AKgAAAAgABAE7AAIAAAAYAAAISodpAAQAAAABAAAIYpydAAEAAAAwAAAQ2uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAE11aGFtbWVkLCBVc21hbiAvU0EvRVhUAAAFkAMAAgAAABQAABCwkAQAAgAAABQAABDEkpEAAgAAAAM3NQAAkpIAAgAAAAM3NQAA6hwABwAACAwAAAikAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMDowMToyNiAxNToxODozNAAyMDIwOjAxOjI2IDE1OjE4OjM0AAAATQB1AGgAYQBtAG0AZQBkACwAIABVAHMAbQBhAG4AIAAvAFMAQQAvAEUAWABUAAAA/+ELKmh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjAtMDEtMjZUMTU6MTg6MzQuNzUwPC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPk11aGFtbWVkLCBVc21hbiAvU0EvRVhUPC9yZGY6bGk+PC9yZGY6U2VxPg0KCQkJPC9kYzpjcmVhdG9yPjwvcmRmOkRlc2NyaXB0aW9uPjwvcmRmOlJERj48L3g6eG1wbWV0YT4NCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgPD94cGFja2V0IGVuZD0ndyc/Pv/bAEMABwUFBgUEBwYFBggHBwgKEQsKCQkKFQ8QDBEYFRoZGBUYFxseJyEbHSUdFxgiLiIlKCkrLCsaIC8zLyoyJyorKv/bAEMBBwgICgkKFAsLFCocGBwqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKv/AABEIAn4CmwMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/APoi91Kx01I31G8t7RZX8uNp5VQO2C20ZPJwrHHoD6VW/wCEk0P/AKDOn/8AgUn+NZvij/kYvBn/AGGpP/TfeVs6pqdpo2lXOpalMsFraxmWWRuiqBRsG5B/wkmh/wDQZ0//AMCk/wAaP+Ek0P8A6DOn/wDgUn+NZWm+LrnVPDa6/b6BeCwlTzIYmdBcun9/y84Axz97OO1bs2qWNvdx2s93DHPKdqRs4BY+gHrTs07Burlf/hJND/6DOn/+BSf40f8ACSaH/wBBnT//AAKT/GoI/Feky+LZvDkdyDqEECzyp2UMTgfXAJx6Vfg1Oxulla3u4ZRD/rCrg7PrS6XAr/8ACSaH/wBBnT//AAKT/Gj/AISTQ/8AoM6f/wCBSf40+013S7+V4rLULed403uqSAlV9T7U+LWNOmtZbmK9geCEbpJFcEIPU0AQ/wDCSaH/ANBnT/8AwKT/ABo/4STQ/wDoM6f/AOBSf41R13xlpmjaDPqUUqXxjiWVIIJV3ShjhduTjnB/I1rzalZ28sUVzcxQyzY2I7gE0AVv+Ek0P/oM6f8A+BSf40f8JJof/QZ0/wD8Ck/xq39utfthtftEf2gYzHu+bkZ6fQZqegDN/wCEk0P/AKDOn/8AgUn+NH/CSaH/ANBnT/8AwKT/ABrSooAzf+Ek0P8A6DOn/wDgUn+NH/CSaH/0GdP/APApP8a0qKAM3/hJND/6DOn/APgUn+NH/CSaH/0GdP8A/ApP8a0qKAM3/hJND/6DOn/+BSf40f8ACSaH/wBBnT//AAKT/GtKigDN/wCEk0P/AKDOn/8AgUn+NH/CSaH/ANBnT/8AwKT/ABrSooAzf+Ek0P8A6DOn/wDgUn+NH/CSaH/0GdP/APApP8a0qKAM3/hJND/6DOn/APgUn+NH/CSaH/0GdP8A/ApP8a0qKAM3/hJND/6DOn/+BSf40f8ACSaH/wBBnT//AAKT/GtKigDN/wCEk0P/AKDOn/8AgUn+NH/CSaH/ANBnT/8AwKT/ABrSooAzf+Ek0P8A6DOn/wDgUn+NH/CSaH/0GdP/APApP8a0qKAM3/hJND/6DOn/APgUn+NH/CSaH/0GdP8A/ApP8a0qKAM3/hJND/6DOn/+BSf40f8ACSaH/wBBnT//AAKT/GtKigDN/wCEk0P/AKDOn/8AgUn+NH/CSaH/ANBnT/8AwKT/ABrSooAzf+Ek0P8A6DOn/wDgUn+NH/CSaH/0GdP/APApP8a0qKAM3/hJND/6DOn/APgUn+NH/CSaH/0GdP8A/ApP8a0q5vx5/wAi7a/9hrSv/Thb0AaX/CSaH/0GdP8A/ApP8aP+Ek0P/oM6f/4FJ/jVnUbmaz02e5toUneJC/lvJsDAcnnB5x7Vy3hbx1c+K/DWm69Y6MFsr+TaEN1maNfM8suV2YIB5OG6U0r7A9DoP+Ek0P8A6DOn/wDgUn+NH/CSaH/0GdP/APApP8alttZ029fbaX1vM3mGLCSAneBkr9QOcVLb6hZ3c0kVtcxSyRHDqjglfrSAq/8ACSaH/wBBnT//AAKT/Gj/AISTQ/8AoM6f/wCBSf41NBq2n3Uxit7yCWQEgqrgnjr/ACNQ2/iLR7t4kttTtZWmcxxhJQd7AZKj3GaAD/hJND/6DOn/APgUn+NH/CSaH/0GdP8A/ApP8atC/tDemzFzEbkDJiDDdj6VXtdf0m9lWK01G2md3MaqkgJLAZI+oHagBv8Awkmh/wDQZ0//AMCk/wAaP+Ek0P8A6DOn/wDgUn+NWW1GzS9Wze6iFywyIi43Hv0qvB4g0i5hMtvqNtLGJRCWSQEBz0X6+1ACf8JJof8A0GdP/wDApP8AGj/hJND/AOgzp/8A4FJ/jVy6u7eygM13MkMYIBd2wMmsDxX460rwnodvqVyxuUu7hLe3WFh87ucAk9lHUnt6GgDT/wCEk0P/AKDOn/8AgUn+NH/CSaH/ANBnT/8AwKT/ABo0nVzqGiR6hfWkumFt2+K5IBXBIzn0OMg8cEcCrFrqdlewyS2l3DNHESsjI4IQjsfSh6AV/wDhJND/AOgzp/8A4FJ/jR/wkmh/9BnT/wDwKT/GpodX064t5Z4b2B4oTiRxIMIfc9qb/bel/Y5Lr7fb+REAZJPMGEBOBn0oAj/4STQ/+gzp/wD4FJ/jR/wkmh/9BnT/APwKT/GnrrmmPJsS/t2fyPtAUSDJi67/AKc9aoeH/FtlrukWF5IPsEt/v8m2nkUu2wkHGCQemaALn/CSaH/0GdP/APApP8aP+Ek0P/oM6f8A+BSf41NJq+nRQRTyXsCxTf6tzIMP9Kz/ABX4otfC2g3eoS+XNJbW73P2YyhHkRBltvB5x/8ArpN2V2NK7si1/wAJJof/AEGdP/8AApP8aP8AhJND/wCgzp//AIFJ/jRoutwax4XsNc2m3gvLSO62yHmNWUNgn2Bqa21bT7wRm1vYJRJGZUKSA7kBwWHsDxmqas7Ep3VyH/hJND/6DOn/APgUn+NH/CSaH/0GdP8A/ApP8alXWNOe0kukvYDBGcPIHGFPuap33iW1tNS0mzhQ3TanO0KvE64jCozFjk8jjHHc0hk//CSaH/0GdP8A/ApP8aP+Ek0P/oM6f/4FJ/jT5dc0uGC4mlv7dY7YMZmLjEYXqT9Miq2leKtJ1fw/b6zb3ca2lwisrOwGMjIB98GgCb/hJND/AOgzp/8A4FJ/jR/wkmh/9BnT/wDwKT/GpJta0y3ht5p7+3SK5IELtIAJCewPenxatp81pJdRXsDwRMUkkEg2qw4IJ7GgCD/hJND/AOgzp/8A4FJ/jR/wkmh/9BnT/wDwKT/Gphq+nNY/bFvYDbBtvmhxtz6Z9farC3ET24uEkVoSu8ODkEeuaAKP/CSaH/0GdP8A/ApP8aP+Ek0P/oM6f/4FJ/jWfoXjTT9Y0a2v7nGm/ap5IYYrmRd0hVivGDg56/jW3aX1rfwmWyuI7iMMVLRsGAI6j607MLlT/hJND/6DOn/+BSf40f8ACSaH/wBBnT//AAKT/GsE+OLhviBd+Eo9LhF1bWP28zyXhWJoi+0dIyQ3tjHvW5Z67DJHGmpeXp96wkY2skoLbUYqWB4yvGc+hpdLh1sO/wCEk0P/AKDOn/8AgUn+NH/CSaH/ANBnT/8AwKT/ABqabV9Ot1hae9gjWcAxFpAA4PQj60261vTLG4aC8v7eCVI/NZHkAIT+99PegCP/AISTQ/8AoM6f/wCBSf40f8JJof8A0GdP/wDApP8AGrFzqdjaWqXN1dwxQOMrIzgBhjPB+lE+p2NsIjcXcMYm5jLOBv8ApQBX/wCEk0P/AKDOn/8AgUn+NH/CSaH/ANBnT/8AwKT/ABrSooAzk8Q6LJNHDHq9g8srBI0W5Qs7HoAM8n2rRrN1T/kI6N/1+t/6TzVpUAc34o/5GLwZ/wBhqT/033lUvix4YvfGHwy1bRtKbF3KivEpOBIUYNtz74xV3xR/yMXgz/sNSf8ApvvK6Sk1dWHF2dzlvCniW3u/C2mrLa3VtfJDHDLYSwMs0TgBTlcZC5/i6Y5zXlHxTttTv/Fd3/Zuk3aQWevaZPJMEdvOby2BlXsqqNi8d+tfQFFW5Xlzf1vcmK5Vy/12PK7zT9UHxQ8dvZQTJLqHh6KOwmCHa8gRxw3Tg4/MVh6B4dtJPghf3013f6XqI8Otpl4lwmxbfytx5QKD1ZueThjXuFVdSsI9U0y4sZ3kSK4QxuYzhsHrUu/K4/11/wAyl8V/66f5HisdqfEGj+NbzwjrGmz6neaFb2cen6ddJMyiJCrn5DxuyVWtK2tJpNY8TX2nW8kekf8ACIQ2edhVWuFV8IB3ZVOCO2cV6DofgfQ/D2pfb9MsoIbnymh8yK2hhyjFSQfLRc8oOucfjXQ02738/wDg/wCZKVreX/A/yPn3UdFRv2V7d1sWOtSWdvaOBGfOIS43bMdeBk/SunutF/tz4razBrU15FpWp6TZtp9xbgbZPKYsUVypAYMd2Bz3r1uihu7b87gtIqPb/gf5HmcltrGnfGiGawT+0NI1KdnuoZYyHsJlgCeerY+4yhV64zkda9Mooo6Jdh9bhRRRSAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACub8ef8i7a/8AYa0r/wBOFvXSVzfjz/kXbX/sNaV/6cLegDV1y4itdBvZZ3CIIHGT6kYA+pNea/AnRJIPA+h3lzcXKXFnbXNrLYzfKIi84cHbgEHCd/WvWaiguYLkObaaOYI5RjGwbaw6g47+1OLtfz/4P+YPW3keSfCTSXabxtLLa7LtPEV3dWDzJjbvVlWRfUEFhnpVXwToWoT/AA3e5spNRtfF2n6Zd6d9nmURosrNu3Y285YKQxJ5J969qqu1/ZpfJZPdQrdSKWSAyAOwHUhepqWrprurfoC0afmeMeGPJX4jfDaGOJopYPDU0U6MhVkkVVDK2e4bdn6+9c54N0y+0rUtDtr+xuIHtvGl5LKXhYKkbQhVYnGME9D3r2rUdD0W5+Iema1c6vJDq1lA8FvZieMK6P8AeyhXcc47HtW82p2Kagtg17breMNy25lXzCME5C5z2P5Vpza3/r4ria05f62seUfDXw/djxZ4gPiZr+31O18QzahbAgKlxFJGY1YErlk25GAcD5a4nw7bz2l5ayNbyRP/AMLBkuyxjIP2YxkeZ/uc4z05r6U86IzmASL5oUOY93zBScZx6ZBpIbmC4aQQTRymJtkgRgdjeh9DUxdmn2t+DX+Q5e8mu9/xv/meW+ANMnj8a+KoPF9lI+orrp1HT55EOHiZDHGyN0IVCQR2zzWj4S8K3Hhn4i+IrG3tgdDvpY9YgY4xFO+9HT81DD0AFegz3ENrH5lzNHCmQN0jBRk9Bk1V0nSxpNoIPtl1eEcebduHfGSQMgDOMnrzSWiX9f10B63/AK/rqcr8QbW7k1zwheYLaTZar5t+Audv7thG7f7KseT2yDXldzpWr2nw7kW+t50huvGwvrCB1O5bXzMl9vUL1P45719GUyOeKZpFikRzE2xwrA7GwDg+hwQfxqoS5Xp6/l/kKS5t/T8/8zjvixJCfhdqjPpdxrCMkZW1tXZWkO9dpyvOAcE+wryy90PxVc6B8UrXTbe4+33xsZowsZT7SnljzvLHfIBGOvbrX0PRWbV7lJ7eR41490221D4X22oeH9MkIu7vT5dXiiiYu8MfBVk9VwMjHQc1UtbJtZ1f40WejwGSS7toEhjVNu9jbPjA9z0PfNe4Vz2i+DrTQ/FGs67bXt5Lc6y0bXMczIYwUG1doCAjA46mnL3rrvf8bf5BH3bPtb8LnmnhBJIfGvhOaeCWKG28Di2mkkjKqkqspZCT3GDke1Y3g6B4NB+FcV1C8bWd/ffa1dCPJDBwN+egO5evXIr6Foq+bX+u7f6k2srf1tY8m8T+FYZfifpumXMVxaeGrvQLjT0e2UbI5XkDMpYghSygYPUkVm+NtIu7bWPFMM9tc3kNx4QW00tzEZGZlJ3pwPv5Ksfz7V6/f6xpulyW0ep6ha2b3Ugit1uJlQzOeirk/MfYVcqGrr7/AMb/AOZSdn934W/yOV8Cs1v8KdEW8hmtXttLiimjuYmjZGSMK2QwB6g89xzXl2i+HNRvf2ZW/sa0ceJobOe0XClZlia4DvGB6sijHfpjrXvdNlljgiaSZ1jjUZZmOAB7mqk783n/AMH/ADFH3eXyPKn8JWWvfD4TWWp6haX19BYkSvECtrPb5ZNyBRjB4bPYD0rFsLjV7rUPh7ceINNSzurfWL03EkMZWOUFGUT4/hDsc57k5717grq6B0YMrDIIOQRS076/O4raW/rax4vp2h67p934k0K3U6ppN1o15Np87wlJ7N5Wybd+BksTkZ5+XNXNNe5i8HfDSzt7G5W9jRIpLkxOUs9tuRKHXuxGUGehz6YPrlFT/wAD8L/5lf8AB/FL/I+c4bK7T4J+ErC+tphPbeKleSCWM7o4lmkJJHZQGHtzVT7Bqw8PeLprTTrm5tY/HCahNbRxFjPaiQksq/xLkKePSvpeir53e/nf8v8AImyf9ev+Z5P4v0620q48N6p4dtZ4NEbW2vtUa0iZ2MksRCzYIPALc8YBx3Fd/wCG9Is/Dvh1bKyubia0jaSRJLpwWAZixwQB8vJxx0rZoqPstD3d/wCuv+Z84aTayJ8MfAtrcW7iS28XCeeJ4zmOISSEuw7LhlOfcV3vwQgnt4vGSzxSRLL4juZoQ6kBo2xtYexx1r1Kir5tP68v8hW1v/XX/M8Z1XSP+El+Pms28d3c2ttc+HPsYurc7Q0olyY92D0HJA54Nb/ia1E3xy8IGaHzLZdOvI5WZcoCwXaCenJBx9K9HoqOiXa/43/zG+v9dv8AI8D+Nel3k1hrek+HtHuVgt9JsgWjR3EoS4GxIx0ARd5J68j0NaHjeJpvGyTSRNIh8FXUG8pkea/3U/3j2HWvbKKTV4uPr+N/8xp2kpdrfhb/ACPFNFhukuPhtPq9vLLoo0GSwuSyErBcNGqkSf3chSuT7ir3iLwtFqHxMtNJv47u18M3fhk6fbPbrxG4kBMe5g20lFXHc7RXrtFW3eV/X8b/AOZK0Vv66f5EVtEILSGEM7iNFUNIcscDGT71LRRUjM3VP+Qjo3/X63/pPNWlWbqn/IR0b/r9b/0nmrSoA5vxR/yMXgz/ALDUn/pvvK6SuW8YTNBrfg+RIZJyutSYjixuP+gXfTJA/Wtf+1rj/oC6h/5C/wDjlAGlRWb/AGtcf9AXUP8AyF/8co/ta4/6Auof+Qv/AI5QBpUVm/2tcf8AQF1D/wAhf/HKP7WuP+gLqH/kL/45QBpUVm/2tcf9AXUP/IX/AMco/ta4/wCgLqH/AJC/+OUAaVFZv9rXH/QF1D/yF/8AHKP7WuP+gLqH/kL/AOOUAaVFZv8Aa1x/0BdQ/wDIX/xyj+1rj/oC6h/5C/8AjlAGlRWb/a1x/wBAXUP/ACF/8co/ta4/6Auof+Qv/jlAGlRWb/a1x/0BdQ/8hf8Axyj+1rj/AKAuof8AkL/45QBpUVm/2tcf9AXUP/IX/wAco/ta4/6Auof+Qv8A45QBpUVm/wBrXH/QF1D/AMhf/HKP7WuP+gLqH/kL/wCOUAaVFZv9rXH/AEBdQ/8AIX/xyj+1rj/oC6h/5C/+OUAaVFZv9rXH/QF1D/yF/wDHKP7WuP8AoC6h/wCQv/jlAGlRWb/a1x/0BdQ/8hf/AByj+1rj/oC6h/5C/wDjlAGlRWb/AGtcf9AXUP8AyF/8co/ta4/6Auof+Qv/AI5QBpUVm/2tcf8AQF1D/wAhf/HKP7WuP+gLqH/kL/45QBpUVm/2tcf9AXUP/IX/AMco/ta4/wCgLqH/AJC/+OUAaVFZv9rXH/QF1D/yF/8AHKP7WuP+gLqH/kL/AOOUAaVFZv8Aa1x/0BdQ/wDIX/xyj+1rj/oC6h/5C/8AjlAGlRWb/a1x/wBAXUP/ACF/8co/ta4/6Auof+Qv/jlAGlRWb/a1x/0BdQ/8hf8Axyj+1rj/AKAuof8AkL/45QBpVzfjz/kXbX/sNaV/6cLetL+1rj/oC6h/5C/+OVznjjU538P2wOk3yf8AE40w5byscX8Bxw/U9PxoAs/FHxBfeF/hjresaT/x+W0H7ptudhZgu7Htuz+FVHh0nStB8Pv9s1G1vYbOOG2TTt0skqlVzuiwysM4JZ1O3OcjNbepSrq+l3OnahoF/Na3UTRSxt5WGVhgj/WVV0C41LTNJisb7Sryf7KPJgmQRBniUAKWHmfexwccHGeM4At38v1G9l8/0JvCs/iWVb1fE8ECRJKBZSqAkskeOfNRWZQwPdWwf7q9K5PW7aCH9ozwtLDDHHJNpV4ZHVAC5G3BJ713X9rXH/QF1D/yF/8AHK5u98M6XqHiuHxHc6Jrx1SDiKZNQZBGvdVUTBQpxyuMHnPWmviT/rYXRo8k8TXGsf2P4+nHmf2rH4vtBagfewpXycf8BxXfax4UvNN8Zz67dXDGxm1e11MNEcyZjt3h+zqvVizMuO2C2cY562eztLnXItWm8O6ibuIDBDoFYjIVmTzNrMAzYJBIycdauzXbXE9vNLoeos9uxePmPAYqVzjzOeCfzpLSKXb/AIH+Q5O7fn/wf8zh7zxneeF/Fksd1CtwHmsk1MspMu+5LrGsJBACR7OQQS25jkHOdu/v57D43aTaW5PkappE/wBpTHBMLqY2+o8xx+NX7yxsr/XLbVrvw3qEl5ageW+6MLxnaWXzMMV3NgkHG44xmoLWC6fxZN4g1LRbxrpITaWix+XiKAsGOSZOWYgE+gAHqS1bT5/loS76/Irapfzz/GzQdIdj9jg0u5v1Ts025YgT9FZv++qw/h/4x8T+MdUurokixttZurK5iKRIkMKp+729XMm7bnPGCa6XWbe5u9Z07XLDRr1dT04PHGZPL2SRSY3ocSf7KkHsR9RTrLSNN03VtQ1LTvDepWtzqPN0YZURZG5+faJcB+T8wGeetJbff+f9Ib1/r+vU5zwXrPiN/iVrfhnxL4iNz9iZrmx2wwKbq3YhQCVjHMZB3YwSW9BivO9M8S694Z+AviXX9I1eeLUV8RyL5kkccmd0iqxO5DknP6DGK9XtPB+i2WrabqcOga6bzS0aO1lk1BnKKzFmBzMdwJY5znsO1RXfgTw1e6LfaTP4T1MWF/efbbiCO5CK8vrxMMDPOBxnnFVF2/rzT/JCer+f6P8AzG+Jdf1rw9q+hWbajcXMfiDUiqtHBCrWsYgz5SswCktIM5bnBI7CqDa/4xtfGXgfSNZvFs31KS/S9igSJ/OSJN0TE7TtbBGQpAzXTa1pGneIdBh0fWPDup3NpA0bRbplEiMn3WEgl3bvfOTk+tRX+g6bqWraVqd3oGsm80jd9jlS72FN33icTDcW7k5z3pJpD6fL8df6+R574X+Ifiq5tdCvtR1f7St14pk0aaE20Sq8IRsMSqghgccgge1dD4T8a+JvFPinWFto8Wula+9hLARGsa2qqV3En94ZN2Dx8uOKs2/w38L2sNtFb+GtdjS1vDfQhdScbJyADJ/r+vHX6+proLfTbC08SXGu2vhvUYb+6QJcPG6Ks2OjMgk2sw6BiM4707rT+ui/VP7ybPX+ur/Rr7jM+K+vav4T0Kw8Q6ZezRWVlfxDU7eOKN/Ntmbaxyykggkcgjqadqms6nZPorJrbFNZv5PLtxDE1w0JjYxrD8u3AwrMXzgE/N0B3NVaPW9JutM1Pw/fz2l1GYpoyYhuU9RkSZFV9QsrHVLrTrm98NX0k2mOXtHzGDESu04xJ0IOMHjpU9LFef8AXkeR6n4m1Hxb8Nvh9qusukl23i+CJ5EQLvCSSKCQOM4Azjin+MfiN4v0ez8ftZa28b6Lq1nBYk2sB8uOUMWU5T5h05OTwOeue7m8AeGptMtNPPhjWY7Wyu2vbeKK+KCOZjkuNsw5Bzj0ycYzU+veC/DviaS9fWPCeoytfCL7TsnEfmmPOxjtlHzDJGeuOOlXzK69b/8ApP8Ak/vD+vz/AM/wMvU/F3izUfGWv6N4Vi/0nRo7J4ophEsM4ky0rOzfPjbwuzGCOaveHfFetp8RL3w54uEtvLcTzT6Q0UaNb3NqvRdwG4SL1OT+XFa76Rp0mvWmsv4c1M6ha232VJ/OXLxddr/vfnGRn5s88006fb2d82qaZ4YvP7RRJBD5kieWjSNudtvmYBY8kgZOOtTsvv8A6/rzDr9xk/CLVLq6h8UaVcO0lvo2vXNnZlh9yEHKpnuFyQPQYFeiVyfhewTwvpktva6NqLzXVxJd3cxEWZp5Dl3/ANZxz0HYACtr+1rj/oC6h/5C/wDjlDDqzSorN/ta4/6Auof+Qv8A45R/a1x/0BdQ/wDIX/xykBpUVm/2tcf9AXUP/IX/AMco/ta4/wCgLqH/AJC/+OUAaVFZv9rXH/QF1D/yF/8AHKP7WuP+gLqH/kL/AOOUAaVFZv8Aa1x/0BdQ/wDIX/xyj+1rj/oC6h/5C/8AjlAGlRWb/a1x/wBAXUP/ACF/8co/ta4/6Auof+Qv/jlAGlRWb/a1x/0BdQ/8hf8Axyj+1rj/AKAuof8AkL/45QBpUVm/2tcf9AXUP/IX/wAco/ta4/6Auof+Qv8A45QBpUVm/wBrXH/QF1D/AMhf/HKP7WuP+gLqH/kL/wCOUAGqf8hHRv8Ar9b/ANJ5q0q56+1KaXVtFVtKvYgb4jc/l4GYJR2c+ufwroaAOb8Uf8jF4M/7DUn/AKb7yrHjPXpfDHg/UdYgt2uJLWLcqKpbGSBuIHJAzk+wNV/FH/IxeDP+w1J/6b7ypPGHiSx8OaXFJf6ppunmeZUU6jJsjkUMDIvQ87M498Un5DW+pR0LxBJr9rJdaJrlpqemvZs6XMaATRTZ4DL0xjOAQDwetcx8MvGXiDx74Jt9VbVbaLUzcPvsxCm0xI6g8feBIPXPWsrSdW+HeheNdS17RfE2gWEd9YNBLZxX/wC7kmLgiQjbheARwD1qh8L9c8O+APBcWm3Pirwpc6lE0224i1Jgu2Rgccx5OCo4pr+vvE/6+47Dxj471jwN41tJ9ThW58JXJWGedI/3lnK2SGOP4OO/v7VpeK/Fd34V8MahraT/ANo2/wBqhjhZIgy28T7d0h28sFDE/gPeqF58QvAGrLqllq3iXQZdOvYhFgXoZmBUg5BAA68YJrn/AAj4j8I+DPCq6FZeOtC1G2W/Zx9tuutsw+50PzA/hR0sC7naW+v3eoaJqeoaNrFpqGnRWHn2l5CqmTzQGLLIvTGAuOAeTWb8N/EWv+NfhtYeIL2/S3mnM7SCGBeNjlVAyD/dJNcfpt94C0LWPEd5oPinw9Y22sacLdbBL8+Us2WzIfl+UYI4APer3wz8VeFvBfwwtvDupeMfDs17bibD29+TG292YclQR97HQ0fZf9dx9v66G58JvFHiLx54Ns9ev7yKMyXE0M8KQqAFUEKy8Zzux14qn4V8VeL/ABN4N8WX1veQHUtI1C4tLSMW67JfJUEbu+Wzjisr4ReJvC/gDwEuhax4y8OT3Ec8kqyWt+WRtxzg7lUj8jUnwy8U+FvB9prsOseMfDkn9pavPqERtb8vtWTbhW3KvIx2py1dl2/HT/gkrTXz/wA/+AdJ4W8YX/i/4ZaPqum323Vr6UQuDCpVZAT5gK44VQGIPXp602bxXqMXxc1Dwzd6xHaafBpKX8cpjjDly+0rkjBHU+tYPgrXvAng/Xtdlg8b6K2lXt0bmytVuRm3aQL5ufqyjAHQfWq0/iPwlcfFbUfElx4p8M3Gm3ekLp6wvqBEgYSbtxGwgD6Gh6tP+tg2TX9b/wCR67o0epRafs1qeO4ulkcebEmwMm47DjsduM+9cTpvj6413VNXsLC8tLTVtPvjANKvU2s8IbG8HglmAYjBI6cdzds/i14NaNzqHivQo3LnYsN6HAXAxkkDnr2rg/GGo+BvGVra3F94p8N22t2dwJINStr4qyoJMgEbfm+XsTjNT1RXRnWa14u1az+I2s6GuqW9pbWuiDUrYyxp80hYrsJPUfL25rnL74q+Iz4Z8C6u0Uelv4gvxZXkEsQxGvmbfMXdyMjnnI6VZj8WeED8XrzxPceLPDcmmz6VHYLGb3MoZZC+4qU245x96qPxJ1/wr4u1LwtLpHi/w1HBoupJezLc3xQuqkZVQqMOg74qo20v/Wv+Qur/AK6f5noc/iX+wNF1jxBqepx3+h2tuJIJUVQ7OrOrrlcA5IQD61B4e1DxbrfgmPXZTZ21/eQ+fbWHl7okQ8oGbO4sRjJzgZ6Vyes+JfAOu+DdT8LTeJ/D9jpt1A/kmC/3skrSF84KgBQ2D3z7Vf8ACnxJ8O6N4TsNL1Pxd4amubO3WDz4b47XCjCnaV44AyM0d/lb8b/oD6W8/wBLfqap8R6xJ8cX8KLdqmmro41LiJS+7zdmzOOnf1rN0TxbrGo+NvFfh+91uG3fSriC3sG8mPdO0qFhuBHOMDpjjNZH/CW+F1+NT+L18X+HDp7aONOEZ1Aibd5u/djZjGOPvVQ0TXPClj478Ta/qHifwtOuqXdtdWapqbb4WiQryTH3z2zxQrde36r9BO+tv60/zO217x5H4f1/StH8R6guirc6f9okvTEGSScEAxKSCBjDH8q6Xw3eajew3kmoTWdzALgiyuLM5WaHapDNyfmyWBxxxXB33jvwXr9r9l8U654S1K1aGNjA93kJMGYtglOVxsweDwcipPg6nhrSZNa0nw54ksNSS4umvbextbozG1hwikZIB+8R27ijvf8ArUey0/rQ9RooopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzfjz/AJF21/7DWlf+nC3rpK5vx5/yLtr/ANhrSv8A04W9AHSUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGbqn/IR0b/r9b/0nmrSrN1T/kI6N/1+t/6TzVpUAc34o/5GLwZ/2GpP/TfeVs6hpGm6tGiarp9rfJGcotzCsgU+oDA4rG8Uf8jF4M/7DUn/AKb7yukoAxf+EL8L/wDQt6R/4ARf/E0f8IX4X/6FvSP/AAAi/wDia2qKAMX/AIQvwv8A9C3pH/gBF/8AE0f8IX4X/wChb0j/AMAIv/ia2qKAMX/hC/C//Qt6R/4ARf8AxNH/AAhfhf8A6FvSP/ACL/4mtqigDF/4Qvwv/wBC3pH/AIARf/E0f8IX4X/6FvSP/ACL/wCJraooAxf+EL8L/wDQt6R/4ARf/E0f8IX4X/6FvSP/AAAi/wDia2qKAMX/AIQvwv8A9C3pH/gBF/8AE0f8IX4X/wChb0j/AMAIv/ia2qKAMX/hC/C//Qt6R/4ARf8AxNH/AAhfhf8A6FvSP/ACL/4mtqigDF/4Qvwv/wBC3pH/AIARf/E0f8IX4X/6FvSP/ACL/wCJraooAxf+EL8L/wDQt6R/4ARf/E0f8IX4X/6FvSP/AAAi/wDia2qKAMX/AIQvwv8A9C3pH/gBF/8AE1a0/wAP6NpNw0+l6RY2UzLsaS2tkjYrkHGVA4yBx7VoUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc348/wCRdtf+w1pX/pwt66Sub8ef8i7a/wDYa0r/ANOFvQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBm6p/yEdG/6/W/9J5q0qzdU/5COjf9frf+k81aVAHN+KP+Ri8Gf9hqT/033ldJXN+KP+Ri8Gf9hqT/ANN95Wf8Xde1Lw38K9a1LRA32yOIIjqMmIMwVn/AEnPbFKTsrjiuZ2OsGoWZumthdweeoy0XmjcB6kZzVivM3TwJ4S+Eel6b4mZV0m9t1Jne3km8yV1DGQsqthyzZBPfp0q0/i7VtS+JD6DoM8aWtz4dOoWrXdqyFJvNMYLBgGA6cEVTVpOJMXePN/Xb9T0KivKfH/xE1zwnqjx272Trb3NkhhUbzJFLkSGTvGdw+XnkZ4OKf4n8b6/pvifxpZ2VzClvomhpqVsrQgkyYJ2k91O0+/PUVLaSv/WiuUk3/XyPU6K838FeMtf1Pxtb6Rrz2ki3nh2HWF+zRFBE7yFdgySSNpHUnnPTpV7xt4k1fR/HHhLS9MuUjt9ZkuI7gPEGwI49wKnsefp04qnFp2ZKkmrr+up3VFeKaF8X9b1TwV4PmnihGpa9qktlLLDEPlSMnJRWIXeflAzx14rYvPG3iy0h020123h0G7lsb64mncIyySQnESL8zKCwIYjJPBAxQ1b+vK493b+t7HqdIWC/eIGTgZNeWxeOfEEfgPw/qGqEWV7qdncSSq8Y88TKuY1SLbyhwSScbQRkisE+M9V8Yw/CrUJLhrD+1r6drmG3A2l4gyhhuB46nByOfaq5He3nYnmXLfyue3LLG8jxpIrPHjeobJXPTI7U+vGrrUddtfE3xQufDLW6anpgsp1kkhDG4QQMxRvovC4x0Gc5NbmsfEj+z/h7P4y064+22MtvbxWcTxrxcOcMzkY4G5cjjkMPSp6X9Px2K62/rQ9JorE8O3WsTSX8OsWs0ccMq/Zbibyw06FATkISAQ24duMe9cJrPxK1fSPHel6a4tZYbzXP7Mlhi+dY4mC+W+/AxLySy8gDHAyCRJuSiuoulz1aivONO8ceINd8T3Q0LTHutLstbbSrsYRPKiWMbpsswYsHPTBG3tmofB/jHxFq2i6nq99PbSWei6lf290nk4kmihTKbccbs4zx60tLX8r/AJf5j62+X9fcemO6xozyMFVRlmY4AHrUdvdQXkImtJ454jwHicMp/EV5d4P+Imr61/wjy64sDL4l0y7ukSCPAt2iYYUHOSpQ85ycj3xXGfCjxff+E/h14DjQLcWWtavPp80RT5kLSHa6n1B654x271Si72/re35k8ytdf1pc+h0ljkLiN1co21gpztPofQ806vnu8+KF54C8I+J9QsbK0m1GbxdcWavJGQj7UUmRwpHzELjjAyc17X4eXXVN3/blza3UDOjWUkKbXKFQWDjpndnGO1SruKl/Wyf6lyXK7ev4Oxs0V4/dfF++hm1fVEt0/svS/EUeim22fPIpyHkz13bsEDpjgjPI3dP8Q+JtV8feKtC0+6tRHo9zYvG08P8AyxlG6VcjqcA4PsPrTSvbz/4H+Ynpfy/4Y9DoryDR/iF4m1vxZBaOVtUfX7nTpLGKBfNjto49yzEtk8ngnocjGDV20+IWtf8ACwdO0m8axeG61W6sJYrVvMWNEjLxNv7ScYZee3AzQle39dv8wel/L/g/5HqVNEsZlaIOpkUBmQHkA9Dj8D+VeJat8VPEmjzeJZTLbzw6P4htrCKN4QN8Mm7cCRjnpgj071sahq+saf4+8ezeH9Ph1DVbPSbN7VWTDPkudpwRkDJIHU9M9Km+il0f+Vx295x6r/Ox6vRXjuu/FO+b4exa74X1KCaZtYgsClzabXhDKAySpn74bJyuBis7xH8T/F2hx+NbqK4sprfw1qFtBEj23zTLKRkMQegGcYAPvVW1t/XT/NE37f1v/ke50Vw1/wCNprH4g2OjXzGxttQihaxlkizDcsS3mIX/AIXAC7R0OT6jHc0W0uF9QooopDCiiigAooooAKKKKACub8ef8i7a/wDYa0r/ANOFvXSVzfjz/kXbX/sNaV/6cLegDpKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDN1T/kI6N/1+t/6TzVpVm6p/yEdG/wCv1v8A0nmrSoA5vxR/yMXgz/sNSf8ApvvK37m2hvLWW2uo1lhmQpJG4yGUjBBFYHij/kYvBn/Yak/9N95VvxfdXdh4O1a+065+zXNpaSzxvsV+UQsAQeMZFJ7DW5jT/DDQ7nw1D4cuJLuXRIJFlisnmJCFTkAP97APbOK1W8KWh8cJ4pWaZb5bL7DtBGwxbt+MY/vc561zPivxZdWGn+HY9G1xHurzVra0uG8lGLxyNhuCMAj2roNQ8ZWdhf8A2VIZbtlu47SUW+GeNn2/MV/ujcMnOR6Gq8/P/L/MXT5f1+Rn658LPD3iDUdSvr9J/P1KW2mlKykAPACI2A7cEg/Wp9U+HmmatqetX1xcXKy61YrYXQRgAYh2HHB68+9ZN34km0e08RSanLf3UNvr8FrG9syK0KuluVHJHy7nwcZOGPFdXca60dxMlnp9xerbXMdtOYSu5GYKcgE8hQ6lumB0zUqzX9dl+g7v+vIz9I8C2GjeILbWLe5uXubbTU0tfMIIMCncoIx1z361Pr/g+08Qa5pWq3NzcRXGks7WvlEYVnG1iQRzkcVHe+NbKztpL0W80+nw3wsJrmEg+XIWCFiCR8gY7SeoOeMc1k6f4outGg1241cXN/a2mt/ZTMpXdDGyxAHbx8ql+e4Bzg0+bmf4/l/mLl5Vb5f19w22+EHhu18M6dokZuvK0y++32U3m4khlznII6jPY0njnR/FV1qmnS+E9SlsWihlWaZrSK6V9zIcbHIwfl6jtxitq78Z2lj4gtNLubaZGvLw2UTnHLiIybivXYQCA3qOmOan0zxMusW9vd6dZTS2N0sphucgKdhIy3orY+U859BRra/9bBs7GBpXgu81u10++8eTfadY08XVtHNAohWWGX5SWRTgEqO3SrFj8L9D0/S/D1lbPcqvh6d57F/M+ZS5JYH1BzT9B8drqfhbS9TvIobe41OGS4hhM2AEVgOTjr8wHQ/WrGl+Nk1i4sobTR7+KS8sXvY1ugkZASRUZCNxIYFh7H1qrtaf11/4IrJlvTPCVlpfiLWtYjlmluNa8v7UshBU7F2rgY4wpx71Wg+H3h+D4fnwaLQto5jZDGzEtyxbO7rnccg1b8QeJ4fD9/o9pNaTztq939kheMqFR9pYbskHGFPQHpVK88afYoZHl0yYm21GOwu8SLiAuEKy57x4kXnGRnpU7q39f1qO+t/6/rQ3NL04aZp8Vt9omuTEgjEs7ZdlHTJ7/WuVf4UeHWvILlBcpJb6w2sx4lJ2ztjd1/hO0cUnxC1vUbLw3cz6ZM9m1rqNpAZUYEyiSSMOvTgYk9etbGpeLINOtr+7FrLcWmmzCG8liZcxnCszBSeVUOC3ORzgHFHNrzdf+Gf+QctlboPsPCWn6X4g1PVrFpoZNUdJbmEP+7aRRgOF7HHX171H4Z8G2Hhaw1CztJZp4NQuZLqZZyDmST756dD6dKdF4la5v9VtIdLus6Y/lzMXjG7MXmKV+bkEEDnBBIzjnC+CNVh1zwPpOpWrXTw3Nuro14waUjplyOp4p20/r+ugr6lPQPh9ovhyaF7BZitrbSWlqkshYW8TvvdVz6t3PPAHSoNA+GPh7w6unR2EUrQaXJJNZQzSF1hkcYdxnkk+/TJxiuwoouwsjhLj4Q+Gr/RdR0vVFnvbbUNQOpSiR9rLcHhnUrgjI4x0rrtJ01dJ02CzSeWdYIliR5jltqjAz6/Xqau0UttBvV3Zy8vw80GXV5b5rdts98mozW+f3clyikLIR685x0JwetWtK8J2mkeKtX163nna61fy/tKuRtPljCYGOMAke/et6ihaAeRWehfEnTdbnn0rVFFlLqLzfYr2yif9282WzODu+6SRx2A966jTfhV4e0nUob6yFws8GpS6lGxlJ2yyptcc/wAJAHHtXa0U72X9f10Dv5/1+pwOofCHQ9SXVVubq9K6rfJf3IDgZlTO0jjgDPStgeB7L/hIdR1hru7+06ikKTbZNnETBkxtwRgjt1ya6aiktNg3dzi9R+Fuh6nptzaTvcL9r1JdTuJUcBpJ1GFPTAAAHA4qDUvhLomrWuuwXtzeOmvXEVzegOBueM5XGBwOn5V3dFH9f19yAwrrwlYX09pJetLOtrPFcrG5+UyxrtRsdsdeOCevQVu0UUXAKKKKACiiigAooooAKKKKACub8ef8i7a/9hrSv/Thb10lc348/wCRdtf+w1pX/pwt6AOkoqK5Wd7Z1tXWOYjCu65C++K4CTxvP4f8OeKtSvdQ/tpdHVXiVoBDLlsgAhQAULdG9m9KTdhpX0PRKK8+17xP4i0Zzptgi6nqd3o8t9bARgbZI2jDKAPvAiTIHquO9XtJ8S6ibDVDqsscKx3jpZXlwnlhrcKn71gP9sso9eKq39fOwul/67nZ0VWsb621C1E1lcpcxglDIhyNw4I+uas0gCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAzdU/5COjf9frf+k81aVZuqf8hHRv+v1v/SeatKgDm/FH/IxeDP8AsNSf+m+8qz4w0/UtX8J6hpmjfZRcXsD25e6dlRFdSpb5QSSM9P1qt4o/5GLwZ/2GpP8A033ldJRuNOxwvirw54o8Q6L4fih/smG707UYb65DTSGNjE2VVDszz3JAx71cTw94ksvGU11pWrWcOh30guLu1lgLzCXaqt5bZAAYKOT0Pauuop31/r+uiF0seaaz4M8W6pp+t2yHRo/7S1e31BGNxL8ixCP5T+76nyV/76PoM7p0HxNZ+NHvtG1Oxi0e/kWbULWeFnkEgRUJiYYHIVc59K66iktP6/rsD1OLfwRcbr/SYpbdPD99eC/dPmMyyFw7xgYxtZhnOcjJGO9Pm8IX899qdo9zbjRdSvVvpsA+eWAQGLGMbT5YO7OeSMd67Gikkl/X9dkNts4LUvA+rXvia21IXVky22si/V5A3mNCYWj8o4HG3cdozg5OcHrb8H+Fdc8K3E2lf2naz+GYUYWEJiP2mPc2drN0KjJA79K7Kin0sLrc83tvAninRvDOjQeHtX0+DVdHWW1jkniZ4Z7Z3Bw4HIb5VPHcVvRaN4hTxppupzzafc20FhJa3EhZ45HZ3R2ZUCkAAxgAFuhPpXVUU763YHnXxVllj1bwT9kkhS4XXVdPOztwIZB82OQMkDPbNbF1bW2neH9STxRdW0d5rrMsiQsdrOYgixx5wWIVBjjJPautoo6W/r+tBdb/ANdf8zhNf8I65qXw8s9FtLm0l1EzwXN5cXjsod0kWViNqnqy49h9KuXXhTUJptWs4prVdI1s+ZeIdxkicqqSBOMEMq9TjB5wa6+il1uPWyRyun6Nr1rq3ie6mXTtmpkPaBJnJUrEI1D/ACcAhQTjOM96m+H2gX/hbwJpmh6q9vLcWMXk+ZbMxVwDwfmAOa6Sind2t/WgrK9wooopDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArm/Hn/Iu2v/Ya0r/04W9dJXN+PP8AkXbX/sNaV/6cLegDX1dNSfSZ10OS3iv9v7lrlSY85/ixzjHpWTP4YGvaZqMXieOAy6nZrZ3CWrEqqLuPDEAk5djnHpXR0UrXA5vRvD15HrUera61u93aWhsbU27MQYiwZnbIGGYqvAyBt6nNHiHwo/iLw1eWNzdbLu4eOVZQPlRopBJGuO6gjnucmukoqrsVjA8IeHZfD1jfG7mWW71G+lv7gRk+WjyEfKmcHAAHJ68nvW/RRQMKKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBm6p/yEdG/6/W/9J5q0qzdU/wCQjo3/AF+t/wCk81aVAHN+KP8AkYvBn/Yak/8ATfeV0lc34o/5GLwZ/wBhqT/033ldJQAUUgdWZlVgWX7wB5FLQAUUUUAFFFFABRUMN3bXEkiW9xFK8R2yKjhih9CB06U/zYzMYhIvmhdxTd8wHrj0oAfRRRQAUUUUAFFFFABRTfMQSiIuvmFdwTPJHrj0p1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc348/5F21/wCw1pX/AKcLeukrm/Hn/Iu2v/Ya0r/04W9AHSUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGbqn/IR0b/r9b/0nmrSrN1T/AJCOjf8AX63/AKTzVpUAc34o/wCRi8Gf9hqT/wBN95XRSypDC8srbURSzE9gOtc74o/5GLwZ/wBhqT/033la2saa2rac1oLua1VyNzw43Ef3eexoA8x8OeIptP8AjleQapextbeKLCOe0RZAyxSxEqIuDw3lnJ9TSeM/iJ4g8P6v40SymgaDQbWyuYEkhB3eawDqT6YzjvXZeKPh/p3iq60m5vLie3n0mYT28lttQiTj5iQPYcdKqa58L9L8QXetz3t5dA63DDDeKhADJEcoBxxzQ9l/XoNW5rvbT/gmV8QvHes+G49Qn0/7Msdppsd9BHw7ynzMSCQfwpgqARg5J69rGteONXl8WXGh+HLF57m10ZdSCKqnzpHbCxksRhcDkjnLD0rS1b4ZaJrk1/LqT3EsmoafHp9wQ+NyIdytgdDnmtBvBtj/AMJHZa7DNPDqFrafYmlRv9dDnO1h0ODyD1FHX+vP/gC6f15f8EwpfEniG8+JGr+HNNe3gEOjQ31uLiPOyVnKlWI7ce/esLWPivqFjdXOo2sUbaXa+JY9Be3kTDsNmZJAeu7ceB0wOld9B4UtLfxtP4millF3PaJZvHxs8tTkD655qjf/AA60PUdY+23MchQ38epNbBsRtcomxZCPoBx0OM0Ldf11/wAg6P8Arp/meeXus6l4a8Y/FbW9JkjD6cdOnaGVMrKoh+ZfbIzyO+K2bjxNHpnxS8Sau9srJZ+E471SQQ5UMzbD+P4811F/8ONF1HVNWvJmuB/bTQnUIlkO2cRABFI7AY5x1zzVuXwVp1x4o1DW52kkk1DTxp08Jx5bQ88Y/E/nS1svT9LFaX/ruv8AglbwPqHiHV9OttU1eaymsb/T4LmEwKVZJXBLpj+4BtwTk5zmud8V/EPVNM1jxYmmrCsHhaytrmRJEz9paUkspPYBAMY79c9K7Pwr4YtfCWhwaTp89xLaW25YFnfcY1Jztz3A7ZqjrfgDR9e1C9urrzk/tGKGG+jjfC3KRMWQN+JI46jiqnZv3SY6L3jIl8U63f8AxIvvD2jywRxN4eTUrRp4s7JWcqA2OcdP1rn/ABT8RPEtl4mlstMCR+Vr1rpgtBCGlkgkj3vOM54zwD0GOa9CTwpaR+OW8URzSrePZCxaPjYYg24DHru5zXH61oXxEHjW9ufDep21vYXEyzItzaQzKMIqkFywkUHb0CnGepoVuZf11/yFrZ3/AK0/z1K3j34lav4U8Rw21sLV4xqtpamH75aCZCWZ+6PuU7Rnkc4qDxn8RPEHh/V/GiWU0DQaDa2VzAkkIO7zWAdSfTGcd66bWfhT4f1zUby+vPtAnvLy3vnKSHCywqVUgemCePena78MNL8QXmt3F5d3S/25FDDdqhABSI5QDjjmp1sv66f5lq1/L/g/5GTqGqXK/GyVbK0iuLmPwjJdW2R8xczDEefQkD8zWRqPxUvm+E+q+IdGvMajpjW6TW13ahJIpHYK6un935sqR6fWu9bwTaP4oXXnvLk3g03+zGIIAaHO7sODu5yKqa18NtJ17T9Wtb2WYHWHhN3KmAzrF/q16cAHnPU1Wlrf1vf8hL4k35fkl+ZyuveOfFOn634ttLe5tPK0DRo9SUmDmSQpkp1+5w3v05rT1T4kTafquifbx/Z2m6xp8MtrePEXia5c8xORyoClcH1PtWvffDnT9Qu9aubi8ujLrdilhdkEDMajHHHBIz+dWLjwFp15o1vpd3PcTWkMUERjZuHWFtycdj0yRyQBmjT+vn/wCNf6+X/BOoooopFBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXN+PP+Rdtf8AsNaV/wCnC3rpK5vx5/yLtr/2GtK/9OFvQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBm6p/yEdG/6/W/9J5q0qzdU/wCQjo3/AF+t/wCk81aVAHN+KP8AkYvBn/Yak/8ATfeVv3UqW9nNNK5jjjjZmcfwgDJNYHij/kYvBn/Yak/9N95U/jGy1nU/DVzp/h4WXn3aNDI95K6KkbAhiNqsS3bt1z2xSew1ucZ4V1rXL5PDSwatLfXt073eqQ3JXbBaNuKjhR84LRjHsa7L/hLbF9QsraCOWeO9naCG4jXMbMqF2Of7oAxnpnis+Lw7rWpar/aOuSWdlJbWU1pZQWEjyLH5oXc7OyqT9xcLt4x1PZumeFtTWw0q31GSztxZabNYtHZszKpYIquuVHOFPXpnHPWrbVv68/8AgfeSr31/r+v0Ney8TWmpTL/Z8ctxbOzpHdIP3bsgycH07bumeM5qhpPjSLUdHt7+Szmi+3O5s4cqzPEv/LQkHCqfU4HI9aZ4f0HW9L8Bf2DcS2CT2tk1naS25fa2E2pI2RlT0yBn6mqNx4FuF1nSLy2js5YLTT/7PktJppFjiQMCrIqjEhGMEPgHAPFJpX0/rf8A4AJu2pqR+OLGWxiu0tbspNZvdxIsWZHCsFKhB82eeOMEcipb/wAZadp4nkkWZ7e1kjiup1T5IGcgBT6kbhkDpkZqex0SWDxRd6vcziXfaQ2kC/3FQszEjGAWZu3ZRXO2/gC5aK40i/uo30N9TfUjsY+fcu0nmiOTIwFVscgksABxS6/13/yHpb+v63NubxBBa69qQu7loLXTreLzEZBtZ5CSpDA5LcY24zyPUVmxarbyePL2/uUnsk03S1W4852Ckyybk+XO3cAh7Z+cCq2seCtX1Oc3IurMyJr8OqJE5YJLHGoRUcgcEAAgAEZXrzw/xH4DvNd0fWLc36Ce8v7e9hYlkDeSseI3K8qpKH7vIznk8UK1r/10/wA39w+tv6/rT8TUn8b2Fstx9oguY2he3QK0f3mmbagz0ByOQcY4Jxmty1vBd2hnjilTDOuyRdjEqSp4PuOD3HNc7e6BqcvhqbT7W10tPtcbpcWzSOI1LBQWDhdzEYY5IGeORjNaGoXv9laKLH7UZ9SNmwgLjDTuoC544yWZePeh7CXQ5jSfE0ep6lBrl7DfRJLd3MFikUoZDFEm1tyqTu3OrEH124687/8AwmVmdJF+trdFUtTdzxNHtkt48Zy6noTg4HU4PpUWheEV0STRoY2jaz0jTjbQgkl2lYrvc8Y6J/48ah1bw5rN6ut29rc2sVvqNzDKrlm3lAsaSxsNvAKxtggnO7tjJbtsv6/4fcFq7sval4vsdNluo3jmlextBe3qxrk28Jzgt6n5W+UcnBpsGvLqWqWH2drm0ga2lu3juIPLaRAQmGVsMmCwIOORXKawYL3xdql0baO5sJrdLO9s0uPJuJ2hd+sbffQhvlwQT/tAiuiv/DWoXWr+IL2Ke3X+0NLSxswxbMRAkJzxwNz5yM9B6Uul0HWz/r+tTJ8O3M8GgaDBby3Nq2s30t3FnMxEG5pAjb23KDHtBPYn3rq9G8QWuuCRrJJvKWSWMSMmAxjfY30+bPB6gZ6VTl0TURrlrdWs9tFBaadJbRKyklJHZTkDgbQEUdc8dOam0DS76yvdUvNQ+zxNfzrILe1cvGu1Qu/JVTuYAZGMcDryaenT+un5Bd7s26KKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzfjz/kXbX/sNaV/6cLeukrm/Hn/ACLtr/2GtK/9OFvQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBm6p/wAhHRv+v1v/AEnmrSrN1T/kI6N/1+t/6TzVpUAc34o/5GLwZ/2GpP8A033ldG7FUZgpYgZCjGT7c1znij/kYvBn/Yak/wDTfeVb8W6smjeFdQuWlCTeQ6wA9XkKnaAPrj+dJ7DWrM3TPiDp+oQ6XNLY31lBq109pZy3AjKyyLv4+R2OCI2IPQjHPIrbvNatrC0v7m8WWGKx4ZnTaJCVDDYT97OQvH8XFcVomn22n+JtGsdNuJdX0zR9KkVpZFVorQgIqeWyqFZ2XeDyWA9M889Y+GLXXfCPhbT59C09F1TWX1S4thZoqW1uMybQuMLlfJjbHXcwPU1py3en9a/8OyU+r/rT/hkeoaTqt9d311aanpUljLCFkjcMZIpY2zjD4A3jBDKM445IINC6vO3jF9G+zwmBbEXRnWYl1JfaFZNuADhiDuP3TwK4FrxoJriXQ7L+zYte8RfY7u5itvLMdvHGUZsgcM7RsA3bzAeuKivreXRrq9bw7YtpNpqGtW2n3ksUJUW9msRd3AAwhaR5AX7b9xweala2/rt/mN6XT/rf/Jnpms3z6Zod9fxJHI9rA8wSVyittUnBYKxA46gH6U7Srm5vNHtLm/tRZ3M0KyS24k3+UxGSu7AzjpnAry3UbGW2fVrbRbddP8O63fWlkqpEYY0VdzXdweBt3qNgY/eYA85BNu4F1pOu6jqOiRyWek65fWdgZFiZdhG/z7kgjILDbGHPUgNyMEiX6f1+P9ag/wCv6+T/AKsepUyaaO3geadwkcalmZjwAK8t1CA+G11u/wDCunSWS3N5Y6fI8UBHkW5O6W4Cgfe/fOSx5z8xq34m8L6AbGx07TNNt57fWNTtluGljEsbJEGkeT5s7pGUFN/LHcBk4GDfb+tv8w23PSqK8yl0ga/4ivNM1GytrSx0u9hh0+GOIvJFEqKyvCm0JDzn96CTj5RtIFTWehaTfabq3iSfTGigg1G6v7a0iTylnKRmIu6DG8vtY/NnO73OVpv/AF0HY9AtLsXfnbYZovKlaI+dGU3Y/iXPVT2Pep68x8PaPB4bt/DdsYpPN0rTrq8lW2iKRNPIRuCgADbl5OBxgL7VHpWjiOy8P3Wo26y3tjYX2q3koi3OJZiCyK3UAl5BgdkHsabSXX+tf8iU7/1/Xc9SorzfwBoc2iXWgaXeI4u9O0WSS4I3bEaeVSI1PTC7H47fL7V6RQ1ZgncKKKKQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACub8ef8i7a/8AYa0r/wBOFvXSVzfjz/kXbX/sNaV/6cLegDo2ZUUs5CqoySTgAVjW3imyn0m41aWKe10qGNpvt1yoSN0XqwBO7GOQSoBHI6iqXxJ0zUtZ+G+tadogLXlxbFEQEAuuRuUE9CV3D8a47xN4fv8AxBoWtaT4Ru7i406+0Zmkhubp5PLut6GONN5Pl5UOGQYC/LwM8royklpf+tj0LTvENtf3yWbQT2lzLbC6hjuAoMsWQCw2k9CRkHBG4cc1Jq+rXGm+Stno19q0smcx2ZiXYB3ZpXRe/TOT6cGuLvota1fxTY6v4QWza5sNDlhBvy4hWeWSIiN9vzZCxuSByDtz1roNNv8AxRp/hK6u/GEGmSarGzeTFo/mGNwcBF+fncWOD26VTt0/rUhf19xLZeL4ryxtZX0y+trm7uJbeGylMXmu0e7ecq5TaNh53Y6eoqtL8RNGS3DwrcXEyi5MttGqiSH7OQJt25gBtLDuc5GMiqup6S+m+JvCGpSSBbPTYLi0uHJwqGSNdrn0GY8Z9WFYXhrwbDJpPiDUdfhuYV1PWby4thCSsrW0+2PZ6jzAgOOCODkEUPW9v6/rctcqs3/W56NDqVvcNai3LSC6i85Cq8BMAhj6ZyAO5/A4t15z4svfEHhuNTo+9DJpdxKvlwCUNdR+WILYDB+XDPwME4Jz1r0KBpHto2mTZIyAuoP3TjkUehPqSUUUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM3VP8AkI6N/wBfrf8ApPNWlWbqn/IR0b/r9b/0nmrSoA5vxR/yMXgz/sNSf+m+8ron2BCZNu1RklugrnfFH/IxeDP+w1J/6b7ytrVL1NN0i8vpRlLaB5mHqFUk/wAqBrVi2t/Y3TFLO6t5mAyVikVsflVOGyt9IkkvL7UZHG5wj3cihYg77igPHGQAM9lArgdC0S70++8G6Rf+XYXsP2jVHnhk3i6dgfNh6AqN0wbHIwvHSprDUbrxDo1vujgMuva40cs0KOI2gtjhnCszYDCDaMHHzg96px10/roTzaX6Hpm0YxgevSlwCMEda4LUfiHMmljXdLt4ZtIj1QaaVkDedcsZhCWjIOAA5PUHIXtT9R8X61p1jqN6U06SCz1mOxRdjq1wjmNdq/MfnDSEZ6HaeBUJp/16f5oppr+vX/I7UT273D2wliaZFDNEGBZQehI6gU92RI2aQqqKMktwAB3rgtU12TS/EWq6lYRLLO1/p+j4lUlWDMCQuD94eexJ6DA4NT3l1NFqHi3VJlh3W8UWm2rx78szKHCspYqTunUZAHcdqfS6/rb/ADQW1/r+u52kE0F1bpPbSRzQyqGSSNgyuD3BHBFPwOOBx09q4hL2HRfE1zamGP8As/w3okbRGMMrjzCR5f3trEiAY4BGRzzW3Y6rqT+KZNLvktAq2v2oiBmLRgsFRST1yVkOcDoPTlu17IlXtdm7gZzjn1owMYxx6UUUhhgelGB6e1FFABjnPeiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArm/Hn/Iu2v/Ya0r/04W9dJXN+PP8AkXbX/sNaV/6cLegDpKQADoAPpS0UAAAHQYooooACARgjIooooACAeozRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZuqf8hHRv8Ar9b/ANJ5q0qzdU/5COjf9frf+k81aVAHN+KP+Ri8Gf8AYak/9N95V3xN4f8A+Em0d9NbVL7TYpD+9exMQaRf7hMiONp74AJ6ZxkGl4o/5GLwZ/2GpP8A033la2tatb6Fod5qt6cQWkLSvjqcDoPc9B7mk9tRrcztP8JxWt7NfX2qahqt/JAbdbq8aMNDGeSqLGiIuSASQuTgZJwKNH8H2Oi2mkW9tPcyR6TbtbQ+aynep2cthRyPLXpjvnOaitrXxPfaZDqF3qI07UDCW/s2CKOS3ViMhXZl3sR0JVkB9KSO6i0/xNrWpahfPDYwxW1tiW4cp52Cx2oTtDEPEAFAJPqarVaE6PUhi8G6ToSyXkMV1d29rJJd2emlVkitpmJZmiULu3Ficbi23J27QTVHwJ4PFtolhe63c315d5a7NpfRqqWl1IxaVkXYGJ3MwDMWwPu4Broj4q0ZIbySW8MX2Jo1uElidHjL8J8hAY7icDA5PSodS8UW9lcadbwW9zcTX9yYQFt3/dqo3OzDGQAPbqR74E+g3rq/6/r9Ri+DbAfYd1zeO1lqMupKzyKTJLJ5gIb5eVAkIGMEALzxUMngXT5bSS3kvL9lk1RdUYmVSTIJPMCY242Z9s4A54GLkPi/RbiR44rmVnjErOn2WUFRHw+Rt4wcj3IIGcGm2fiG1/se1uL6+W4a7ha5ja3spYi0OQQ3lks6gBlBJxzzxnFLs+3/AA/6fgPd2f8AX9X/ABC98J2V8mrrNPcgaqUaTayjymVVVSny9RsU/NuGc9iRU+n6Bb6frF3qiT3E11eQxQzNKyncELEHgDn5zx0HYCuY8D6hPH4f0qOS9uFk1KW4v4475bi7c2m4lFErP8pCtEfmLdcY5zXT2HibSdUgtZrC6adLtpkhKwv8xiJWTgrkYIIycAnGM5FOzROhq0Vi2Pi7RNRWE2l2zCfzfL3W8ibjE4Rx8yjkMQMdTnjNXtI1ay13SbfU9Km8+zuk3wy7GXcvrhgCPxFFmMuUUUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArm/Hn/ACLtr/2GtK/9OFvXSVzfjz/kXbX/ALDWlf8Apwt6AOkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM3VP+Qjo3/X63/pPNWlWbqn/IR0b/r9b/0nmrSoA5vxR/yMXgz/ALDUn/pvvK0fEmhw+JPDd7pFw5jS6iKCQDOxuqtjvggHHtWd4o/5GLwZ/wBhqT/033ldE7rFG0kjBEUFmZjgADuaT2GjM05vEEjvHrEWnwJGRsms5nkab1yjIBH9Nz9eo61y974N1u7js7yeXT7i/stcl1RbZ3dYbhSHSJWfaSrKhQ52tgr36joF8VwSxrc2un6hc6a0XmDUYolMR9AFLCRs9dwQrjvV2yv7m51jUrWW1jjt7Ro1inSYsZSybmDKVG0jI6Fsgjp0qtU79RXVrGI/hq9SPWLpodPv73WcC6imZ4o9ioESNXAY4UbjkryWPC9ptM0PWLCTSTd30OovYaY9s9zNuWSaZinzEcjBCDnOevBzx0tRmeJbhIC4811LqncqMAn9R+dIDlLTwlfab8MZvD9rcQzancwyC4uZWKrJLKSZWyASOWbHHpTL3wnqkt94iktZrSNdV0yK0glywaAorrsC44T5924EnJPy966y7nNraSzrBLcGNSwihALv7AEgZ/Gqmv6jcaR4fvNQs7aG6mtojIsM05hV8dRvCtg46ccnA460N7glsZcuhaouvTXVpLaR2sWj/YrFMtmOUkliRjAX5YuQSflPFU9I8LanpFvYx2v2OJbHRmsoYxK7BZjtJOdoyCUBLYz14rqIbt5L6W2e0mj8qJH84geU5bdlVOckjbzkD7w/CzT8v66/5iXf+un+RxNl4HutJsktNOmg8ux0NrCxd2YMbh+ZJXwOMlY+Rk8t7Z6vStPi0nR7TT7ZFjhtYVhRU6KqjAH6Vboobb/r+u4W/r+vQKKw7fXrxpL5bjSmcW+orZx/YphMWRlQ+a24JtA3/MBuxg4zVbWPGKaVqDoti9xZ2ziO8ulkA8mRlLIirj52PygjIxvTGScBeYzpaKyNF1bUL+4u7fVdFm02S3KlZPNEsMysMja+ASw6MNuAehYc1evrtrK3WVLW4ui0iR+XbqCw3MBuOSOBnJ9getAFmis+yv7m51jUrWW1jjt7Ro1inSYsZSybmDKVG0jI6Fsgjp0rQoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArm/Hn/ACLtr/2GtK/9OFvXSVzfjz/kXbX/ALDWlf8Apwt6AOkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM3VP+Qjo3/X63/pPNWlWbqn/IR0b/r9b/0nmrSoA5vxR/yMXgz/ALDUn/pvvKseNbG71PwVqtnpwL3E1uwWNTgyDug92GV/Gq/ij/kYvBn/AGGpP/TfeV0lJ6oa0ZRtdSgu1VILa6C9CstpJEFH/AwP0zXF2sV7qI0y71y01CK0ury6vbq2W2kYswIS3jkQAtt8vnBGNyDNdrJrOlw6oumzalaR37R+aLVp1EpT+9sznHviporyCa8ntY3JmtwpkUqRgNnByRg9D09KrrcXSx53JpN7Jocd1Npk9pdQ6lJqFnpYtTNCYyDGsLhMqpZRvzxsZgfUHQ1fSGXUNfurfTPMMGkxadpqi0LkswfJBxyvzxg84AVs967uil0t/Xb8h9b/ANdzz/WfBdnBJoOm2Onl0murf7ddrCW2wWoZ4144UFiE/wB1iOapzWWp+IpNLOpaVPBc3GutJeytCwNtbwMxiRWxyj+XHnB2ne3rXpE88NrbvPcypDDGu55JGCqo9ST0FMvb2DTrKW7u3KQQqXkcIW2qOpwATgVXNrd/1/VibaWX9f1c861C2utTsZzDo11bya14iWO4Y2b7oraHgyHjgOsJwx/57e9WbvS7zxFcRrd6e8K3GvC5nd4GBhhtkATDED7zouD0IdiMiu9jvLaW6e2jnja4jRZHhDjeitnaSvUA7TjPXB9KmqV7v9en+Q277f1v/meaeH/D97fahod/qNrcWRk1G81hovKZPJBBjhhYYwhKSbiDgkqfSuo11ZLjXraK5sJruxhtJZ1jVGaOafKhUfAI4BYgNxk56rx0dFHRJdA6tvqeb+GvD5itfCq61ZzLJZx3OrXDvA22G5kPEZYjgKJXwD2jX0rP07w4Nc03w+LjSLW3/tTV5NYuo/s4BS2jJaJSMd8wAj3PHWvS9Q0iz1SS3e9jdzbOXj2SunUYIbaRuUg8q2QeOOKWy0ix06a4ls4BG9xIZJDuJ5JycZPygnnAwMknqTVc2t/63v8A5fcLW1v6/rV/ecDMt9cSC5TTL6ytNT8QMNR8m0kEptoUKR5ULuKSNEpJxjbIexzW1feHrC58R6HHb6dJDZW1zLqbFYG2ecqLGi9MJneWxxzHnHeulvdUstPkhjvLhYmmYKgIJzkhcnHQZZRk8ZYDuKlmu7a3lgiuLiKKS4cpCjuFMrYJ2qD1OATgdgaSdrWG9bnnipq+onR57+3u7a2vb+6u7uJ7OaUZGEt45Y1wQuzk7sDcgzXZeGNKh0bQ1tbdZlUyyynzkVCSzliQq8KOeB2GM85rXopbKyDdhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc348/wCRdtf+w1pX/pwt66Sub8ef8i7a/wDYa0r/ANOFvQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBm6p/yEdG/6/W/9J5q0qzdU/5COjf9frf+k81aVAHN+KP+Ri8Gf9hqT/033lT+Nb+60vwTqt5YbhPHbttdf+WWeC//AAEEt+FQeKP+Ri8Gf9hqT/033ldGyq6FXUMrDBBGQRSeqGtGZcWh6Ta6GmkrDGLRgEAfDGRsfeJP3mOM5OT3rnbLW7vU74JozRw/2veXLG7Zdxit7cLFuUHgsW2kZyBuJweh6y00rTtPJNhYWtsT18mFUz+Qpn9h6SbSG1Ol2f2e3/1MP2dNkf8AurjA/Cn1uLpY4g+ItYl8Ox3en6nLd2FrqrRXOoxxw+fJZpkGYLt2ECQEMVUZVWK4NWNYm1SLXtWuv7avooNG0MEiGOARy3EgckgNGxDAIhxkj5lGMZB7KbStPuBGJ7C1lEQAjDwqdgHTGRxinS6dYzGUzWdvIZmVpd8SneVxtJ45IwMZ6YFHS39dv68w6/16nDawPE9tZ6JaXGvSte6ncWtt5CWlv0UO1y8hKMCGQE4ULgqoB5OY9Y8Q3fiC3sl0m7ItdW1R9Mht1jBEsKMRcTM2NwIEcm3BAwRkHIx6BNZ21xNFNPbxSywkmJ3QFo88HaT0z7VDHpGmwyCSLT7VHEhlDLCoIc5y2cdTk5PXmqum7v8Ar+v1YtUrf1/X+RxOoa7e2yald6XqTXE19rcOmWAMER27SolAIUFlU+cTuyQEOCOtT6trmq3l1ENE1G4hM+uRWluscEZR4UjDz7tyE7TiQZBByFwex6xdC0hI4kTSrJUhma4iUW6AJKc5cDHDHc2SOfmPrUsOmWFu263sreJtzvlIlU7nOXPA6seSe/epWm/9bf8AB+8p+X9b/wDAOH0bxDr+q6jpRtbvzrO51a9yzwoPMsYgy7shR/y0KBSOcEZLV0PiB9VfxBolvpOomzhLTTXwMaMrwKgH8Skgh3TBBHfOa2INNsbVbdbWzt4VtozFAI4lXykOMquB8o4HA9BWZL4aS98US6rqxtL2AWywW1tJaAmD5izNvLHJb5c4A+6KfZC3uzldK8U6xe2cWmR3V3c3E0d1cQXyWqCea3WXZC4yohUsCTuK7cAfL81W9KuvEV7q8emjX1luI9ESW6uI7eKS3WaRyI5EwoLNhH/i2kYO0ZrsrjTbG7milurK3mkgBETyRKxjBxnaSOM4HT0qG8sJ2ZZNKnhsZmmV53NsJPPQAja3IPpznIxSW39f1/wwPVnmuqxajF4iub7S9e1G6vNQ12302CJoLZ4xDEPNkHMJIVMyjIIOVGSTknp7iS9g8TCHUNfaZbKxub6dY7SFVhVm2wkblZgQBLg7udnINdDpWhWOkWNtb28Su1vvKzSKDIWc7pGzjqxJJx1qw+m2MlxNPJZW7zXEQhmkaJS0kYzhGOMlfmbg8cn1o2S/rp/TDr/Xf/LQ4zQtW8SR6fYjUp2uNQXRZry5t7pY4z5pZfJ3lFULn94OMDC8jNQ2HiPX7PS7nXL+Se606LTDeTfarNYgJ8cQwBcNs7lm35yMMecdbrOhrqUEhtJVsbyTyg90kIZpI0fd5TdCUOWBGRwzYxmq+meF7WxnnkeGxCTwmGW3tLTyYZATnLJuYMe2fQn1p3vf+u/9fILWS/rscxqup+IrWG+mk1e5hM32WKyhit4Fdp5JNvyRujMsZHB8wljtYjZjJ2Z77Xnj8TJZXEck9vtjsV2KD5ghV3Vc9fvDG7PzZzxwN+PSNNhSBItPtY1t38yFVgUCJsEbl44OGIyOxPrTn0uwlV1lsbZ1kYu4aFTuYjBJ45JHel3DsV/D19Hqeg2t9bXzX9vcIJIp3jCMy4/iAAG7rngc54HStKmQwxW8KQ28aRRRqFREUKqgdgB0FPpu19BLYKKKKQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACub8ef8i7a/9hrSv/Thb10lc348/wCRdtf+w1pX/pwt6AOkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM3VP8AkI6N/wBfrf8ApPNWlWbqn/IR0b/r9b/0nmrSoA5vxR/yMXgz/sNSf+m+8rb1K6istJu7q5AaGCB5JARnKqpJ4+grE8Uf8jF4M/7DUn/pvvKueJ/D3/CT6O2mvqt/psMh/etYmINKv9wl0b5fXGM9OmRSew1ucX4H0Rv7Ht49Y0C40y+0xY743NzJGHnldpGZQ0bviJfugMc4x8owK3PD/jaTVtMsLy9t4bVLmzub+QbjlbdHCxyYPTepDc+4q9D4Sl3XR1PxHrGqfaLV7ULcm3QRK/VlEUSDd7nNOXwdZA3HmXV5ILjTl091Z0A2Dd8wAUAMd2D/AA4A44q207/1/XQlLv8A1/WpzXgzUb3w9pFsdesorNNRt7zV50jXD22JFYKQOCNkiqAORs7543ovFF3b3kia1aRWiQ6c+oXCRyeY8C7sIh9WIDngYyMDOMmyvhO3fTLy21C+vL+4vYTDLfzmMTBOwXYiooB5ACgZ5OTSP4PsJ21R7ue5uX1S0S0uXkZQSq78MCFGD859hxgDmpfkP1/r+tSte63r1noV5fXdlb2UgtRJbox80LMzbUibDAsxJXOAACQAWqrL4quba/m0HTpIdS1PTIIvtPylnmkcZVdisTGCMEyN8o3DrzjTuPCcd9pNvZanquo3rQXUV19plaNZJGjfcisERV2ggdFB4znPNTp4bgj1271JLy8VbwpJNZrIBC0iAKJOBuztVQRu2kKMin/X9f12AzV8R6pLqF0tpDZz6dZXksN3eliggRYQ+duTvIc7Tgjp78UfDniCax0+zGoWMdklxp9xq90rTOzQAuG5DEkZDnjPBBAwBW5b+FLK28I3Hh6Oe6NvcJMstwXXznMpZncnbjcSxPTHtUd34Osby8vrmW6vN99YrYyL5ikKqlyGXKnDfvG9R044pdLf1/Vx9f6/ra5lS+MtRtdLM91bWqXUWif2ldW+SPs7HO1S2eQxDKBgcqefTY0rXrnUfE2oabLZeTDaWtvN5hPIeQyZQ+4CK30cZpbzwnY332jz5rrNzLbySkOMssDBljJIyUJByD13N0zWhZ6bDZXt9dRPI0l9KssgdsgEIqAAemEHrVXV3/X9f8AnoXKKKKkYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc348/5F21/7DWlf+nC3rpK5vx5/wAi7a/9hrSv/Thb0Ab12ty1q62LxxznhXlUsq++ARnjtkfWuFvfEWt+BtH8SXOvX669Dplil5BcNAlu5d2dRCwTjGVUg4zhuc9a7TVm1NNLnOhRWk1/j9yl5K0cWc9WZVY8DnAHPTjrXJWvhjxBrvhvV9C8awaPb2moQFDLpc0ssskjdZGMiKARgY4PYcAYpO9nYpWurlzStWv7DxbZ6Jql9JqDanp8l+kkiRp5DI0YaNQijKfvARuywwcsc8XPGt01l4fe4PiiHwxEjDffywxyY9FHmfLz9CT2xWcvguTW777T4tSI+TYtp0MdldyjzI2dGaUuAjIzGNflUnGD8zZ4vWmhXHhW2t7HwfY20li8rPdJqGpTl1zgbkdlkJ6fdOB7jmqdun9a/wCX/BIX9fd/mUZPEN7eR+F9JS+WC+1y1eeW+sgjhFjiVmaPeGXlnXGQwxnr1rlrv4i6vNZ3UCXK2DaZeX1lLfrGjfabmDYYIdrAjMwc5VcMSpCkV17eD20y20afREgmvtGM3kx3EhhjlWYHehZVYoMkEYU42ge9WPDnhiXw1pN8lpNHLf6lfy391LJnYJJWBbaOpCrgAHGcDOM0dX/XX/IpNJLv/wAP/wAAswa6rvZfbrm2sSwRJo5ZApa4ZM+SuepAySBz096264fxh4DudcjiTTLiBAdNuNMlFzn5VmMZM4wDukBj6HGd2dwxz2lvF5FtFDvZ/LQLubq2BjJoFsSUUUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM3VP+Qjo3/X63/pPNWlWbqn/ACEdG/6/W/8ASeatKgDm/FH/ACMXgz/sNSf+m+8roZ5BFbySF1QIhYswyFwOprnvFH/IxeDP+w1J/wCm+8qfxjaa1qPhq60/w7DYyT3kbQO97cvCsaMpBYFY3Jbnpx654wU9hrc5vwb411DxboMF5aaxoVzd4Wa6tbSBnNvC0mAHxOdj7MnB7g8HGK6yx8TaRqVtDcWV35kU4mKP5bqMQttkJyOAG45x7VLNZSnSpvskUFtqElp5KEMSiMFO0ZwDtBY84Bx2rn9C8LahoktoLcWa29lpMdlbw+a7BX35lJ+UZBCqd3UnORVO2v8AXf8A4BK/r8Dag8UaPPpv29LsralY3WSWJ4w4c4TbuA3bjwAM5yMdRWZ4p8Rwp4P1O40zUJ7K7hZII3EIWVJ3KiNdkqEfMWXqvIPHrWYPBeppp+myQQ6fDNp+qvqMWlC4drVN0bJ5ay+WCAGYuD5eATgDvVi/8J6m95balH9iv7xdS+3zQTSvbxFhD5UYBCyEhBzgjlucr0osmNNo34/EOmJbzGW8bdazLbSiWJkkMpAKqEKgksGBG0c54pR4k0nyJZjdhFiuBasHRlbziAwjCkZLYYcAE9uxrK/4Ru/g1q01NTZ3tw1zLNdeaWiVC0aRq8YAbJVU24JGd7HcOlZ1l4V8QafBpl2X0/UNRtr67uZ0nmdI389jh1cRsQyJhQNuMEjPej1F6G3P4tsvOsIrBLi6e9umt/lt5P3Wz/WFxtyuOnI6ke5FkeKNHaR0juzLsSV98ULujCI4kwwBDFTwQCTnior7SL6+1VZnuIo4hp81sHjBEiSSFfmA9gg5z+HPHO6H4I1HS/h++g+VYR3ZtTY/aluppmeIkBn3uu5PlLERjKg4AIFLp/X9f8OPr/X9f8MbVx420Y2bvb37ROUgKSS2E7KpnJEWVABOSMYyCDwcZFX5fEelQrK0l1gRXUVo37t8+bJt2KBjnO9TkcYOc9ap6z4ek1C+0BbUQJp+mXf2mWFiRuKoyx4AGDhm3YJHKg1kWvhDVn1Kzu9Uls5TBq9zqLrHK+HLKyQ8FeSqEDHYrkE9KrS/l/w3/BFrbz/4f/gG+3ivRkvY7SS7KTyXLWqI8Mi5lVC5Xlf7oJB6HHGauaXq1lrVkbvTZvOhEskJbYy4dHKMMEA8MpH4VzGl+D762jsLi/ktpr63W7uXbzGZftk7AgjIyUUblBIzjHFbfhLQv+Ea8J6fpBYO9tCBLIDnzJDy7k4GSWJOcd6VlbzG9zYooopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc348/5F21/7DWlf+nC3rpK5vx5/yLtr/wBhrSv/AE4W9AHSUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGbqn/IR0b/AK/W/wDSeatKs3VP+Qjo3/X63/pPNWlQBzfij/kYvBn/AGGpP/TfeV0UpZYnMYVnCkqGbaCfc4OB74Nc74o/5GLwZ/2GpP8A033lWfF93c2vhe+XT7W5ubueFoYEt4i5DMMBjjoBnP4etJ7DW5zfh/4kXmow6Nda1olvp9lrd09pYzW1+1yzSLvwWUxJhGEbEMCeMZAzXX3HiDRrOa6iu9WsYJLOMTXKS3KKYEPRnBPyqfU8Vi/8IjZaT4fuJPDlvKdQjsGisDczyOIGEZVBGjtiLPGQoX3rm7mFNJ8IRhrS986+to9KiiaExtGZWAlCRjLs+1WkZyWztGCecXK3QlXe/wDX9foegNrmlJHdyNqdmEsoxJdN564gQjcGfn5QRzk9qqW3i/w9daPZ6oms2KWV9J5VrNJcoqzPkjapJ5bIPy9fbNc/qGkXM0Os6hYWEsS3VlFpVpbJGEYQljvmK5BH+tJ2nBAT3xRqunahJd6/FbabNLc6nBFZWcjECK2tzGFdic4G12clRy3y4yOQtP6/r/hh/wBf1/Wp2Ut/aQ3cdrNdQR3Eil0heQB3UEAkL1IBI59xWRH448LSapLpy+IdL+1xzLbmI3sYYytkCMDdktkYx68dQaotpbDxra3EFg8ieQLa8e4XcjxxfPBKpPG8SFgB1+Yk9AaydN8P6nrKaO2sxT22dRudWvUcDlslYYTz2Vx/3647GhLXy/r9A6ef/A/zOyn8QaNa2K3tzq9jDaPIYVuJLlFjZwxUqGJxu3AjHXIxTZfEehwXTW0+s6fHcLOlu0T3SBxKwyseCc7iOQvU1yUvhub/AISnV7VLOa20uW2gjtYbKFI4pIyWM0e45Ee5mJfChmGMEkYEUcZ8WLqi6ZZsItT1Hyri9ljZVS1g2p+7J+8WaNsbeBuLHoATrb+ugHaR69pU2uXGjxX9u+oWsQmntlkBeJD0LDqOo/T1FS2Gq6dqlo11pl/a3lurMjTW8yyIGXqCwJGR3ridf0vVb28kmSzuhaSa7BJfrHjdNZxRYAAByy+YoYqOoYjB5FRanper3Oqwapcafdpp93rETXllEQzrbRQssbOqk5Bk2syjJ27QRwRRFXX9eX+f4A9P69f8vxO3g17SLrSn1S21Wxm0+Pdvu47lGiXb97Lg4GO/PFTf2lY/2Z/aP223+w+X5n2rzV8rZ/e35xj3zXP6nC48QWOovpMsttFBO6Qxxhma5JjEbMBwCUVgGPCg8kVlaJoV/olxpX9u232sN9su5VtYzJHBdzTK6qB6BS6hyAPvE4zSWv8AX9f16h/X9f1+R182vaRb6XFqVxqtjFYTbfLunuEWJ933cOTg57c81O+oWcbXAku4FNsgknDSAeUpBIZuflGAeT6GuYs9PktvGGoG50lvscljDFZRRRqbdctIZ19FYsyliQNwAxnBFZmraPfz6pfm0sJol1HVbW3nlSMH/Q4VDkDB+6zeYpP+39cPrYDuf7Ssf7QNh9st/tioHNt5q+YFOcHbnODtPPsfSrNczpVtcP4uuL17OaGG4hEk0dwikQ3C4jVo2774+uOm1ehJFdNS6AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzfjz/kXbX/ALDWlf8Apwt66Sub8ef8i7a/9hrSv/Thb0AdJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZuqf8hHRv+v1v/SeatKs3VP8AkI6N/wBfrf8ApPNWlQBzfij/AJGLwZ/2GpP/AE33ldGzBVLHOAMnAyfyrnPFH/IxeDP+w1J/6b7ytHxHqqaJ4bv9Rd1UwQM0e443Pj5V+pbAH1pPRDWrItO8WaJqskSWN8rmd3jhLxsgldCQ6qWADMuDkDkYPpV660vT764t572xtrma1bfBJNCrtE3qpIyp9xXFR+BYdK8L6OmsX3m2fhuNrxUgRonkmEbhpHkDEnl3b5QpyQc1iG58Q+DPCXh64vLrVLnUdXkj097We5WVbRpWaQvvlb5pAPkXe5H3RzzutpX07k3PWqK8t1P+1/DraBqUetXYt38Qpb3Vh9ue6jEcq+WVaRxvYhhu2ghVLEAfKDWnPK8OpXuj6tqeo2+n2dm2qTTfa2SaQzSybYhIuGCptwAp7oM4GDPS/wDW1yrf187HfM6pjcwXccDJ6n0oZgqljnAGTgZP5V5fbXF5Pb6Vf+KBdtrWg6C+pXNrHdyRbpT/AKveiMFZiscgIII5IxjirVhf6gNGvNe1K/mjuLnTgqWz3QcNJKwETLEjtFGN3yrtYswJ3EkU2rX/AK/rYS1a/r+tzsrfXNJ1a1sxE7TwamriAPbvtlVR82QV4GP72M9s1dsbCz0yzS0020gs7aP7kNvGI0X6KOBXJ32opoV3cx2MAEGh6VHDb5X5TJM4VVPptEcZPs9TaAs6eN7+2Gp3l9b2dlH5sk8pZZLiRyXwo+UbVjThQAN57k5OtkCva7OuooopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzfjz/kXbX/sNaV/6cLeukrm/Hn/ACLtr/2GtK/9OFvQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBm6p/wAhHRv+v1v/AEnmrSrN1T/kI6N/1+t/6TzVpUAc34o/5GLwZ/2GpP8A033lbt3YWd/GqX1rBcopyqzRhwD681heKP8AkYvBn/Yak/8ATfeVs6teR6dot7ezgNFb27yuG6EKpJH6UnsNbljyY/I8ny08rbt2bRtx0xj0pJ7eG6haG5hjmib7ySKGU/ga8r8N+Db/AE/TdCWSwOgtorvqF/qJEWb13V2aFRGxbyg0hzv2nCKAD1G1Z+M9fTw7ouo6naWv2jW3jt7S0SF43EshLBmy5wixBmI6kqcdQBbiSmd55Ue1V2LhCCox936VU1OXS7KAahrMlnbxWxyLm7ZVWIk4+833c5Arl9V8V6xYm+s7ZLS4vob+1s7ZvIYJM0oDMm3fkFEO8nPTtUPiPxFfCHUNIkijne51G30y2aBWUyCRA8oIyeVj3HPT8jU2b2/rb/Meh3Ahi81pRGnmOoVn2jLKOgz6cn86ii0+zhtvs8NpBHBu3eUkQC5znOMYznmuQ1XxfqtjZm9tFsp7WHXoNNlYxsN0TtHG7KQ/DLI7jnI+Xpxzo3msawNbsbPTvssqXbTyAtbvxCioFbO/jDuMnHzDoBmhaq6/rZ/qN3W50T20D+bvhjbzl2yZQHePQ+opY4IomLRRIhYAEqoGQOlcbP4q1e00W+vbl9N36bJFaSrHE5F3ckJvSPLAqN7hFzuOQaTXPF2safqi2un29rcmbWYNPhQxNl0MYkl53dVXcc4xwBg84e7sv6/q4ulztqK4238Y3l9JFb6bBBdSXeqTWlvOAVjWGEfvZmGcnDhkwCMnHQc0j+K9VN9bWVmtpdytq72MkiQPtaJIRI7gbztKsdhJJGfypLW3n/X6g9L+R2dFclpfijUNXWOOyS1Zpry6SO5ZGEYt4G2GTbuyxLkKBuGc7u2KpWvjTVLnQrHVzDax6fdX80Bu1ieREhVmSKUgMCFcrnf0UMOCOaFqN6HdUU2PeI180qXwNxUYBPfFOoEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc348/wCRdtf+w1pX/pwt66Sub8ef8i7a/wDYa0r/ANOFvQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBm6p/yEdG/6/W/9J5q0qzdU/5COjf9frf+k81aVAHN+KP+Ri8Gf9hqT/033laGv+HNO8T2AstYW5e3DbikF5Nb7v8AeMbKWHscis/xR/yMXgz/ALDUn/pvvK37oE2cwWZ4CY2xKgBaPj7w3AjI68gj2pPYaI5rC3uNLfT51eS2khMLq8jFmQjBBbO4nHfOfeotU0aw1mzW21CDfHGweNkdo3iYDAZHUhkYAnlSDzXAeErvxN4j8C6LJP4ru4b64X+0L2+Frbfu7c52RBTFtG4c56jBOcYWuoPjazeO6ktrO9mhh09r+KdRGq3Ma9SgdwR14LhVPYkA1Uk03cleRT1bwcdS1zS7dbCCHQ7J3uTLbapPbXP2hlK78RqC3BYEmQE7znpg9HDounW72zQWkcZtS5h28BS/3mx3J9TzyfU1h2DS3F3oD39/fG4t9Pkurnzm8ln3BVAmijPl55Y9Dgocd6reGtYGn+GLUiHUNQu77zb23shO004gL5Ul534AUp95hycD0pu60/r+v8g0ev8AX9f5mi/hW1ltZNHa0hj0Xzku1VZnaV5/OMr7t3RdwU8E5ywwOK2V0+2XUzqAj/0kwiDfuOAgJOAucDk8kDJwM9BWLb+NtOvEt5rKC5uLW6sXvYLlAgWQKcNHgsGDjPdQv+1waJ/G+nJosWo2lvdXvmWSX5t4FRZY4GGQ7B2UL34JydpwDilb+v69B36f10/4BoDw5pX9rPqRtA1y7CT53Zo1cDHmLGTsV8cbwAxHBNOtNA02ykjkt7fDxSTSozyM5DStukOWJ5J/IcDA4rI1G9h/t3ULgPdBLLRi86C4ljT5ySnyggK4Eb/MBuG4cjikh1hPCnh+3sLv7dq11p9kst/IjiSSJNrEyO0j5OSrAAFmPoQCQLb+v66B1/r+updHg7RE0i002K1lht7Ni1uYbqWOSMk5OJFYPg55GcHoa0LbSNPszB9jtIrcW8bxRLEuxUVyCwAHHJUHPX8zVmGQywpIUaMuoYo+Ny5HQ44zT6GG+pj23hTR7S3sILa2kji0+NordVuJOEbGVb5vnHA4bPIBqOLwZoUNjZ2cVpIltZIkcUQuZQrIudquN37xRk8PuFblFF2AUUUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACub8ef8i7a/9hrSv/Thb10lc348/wCRdtf+w1pX/pwt6AOkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM3VP8AkI6N/wBfrf8ApPNWlWbqn/IR0b/r9b/0nmrSoA5vxR/yMXgz/sNSf+m+8rdv7Y3mm3NqknlNNE0YkxnaSCM446ZrC8Uf8jF4M/7DUn/pvvK6SjcNjn7Hwha6f4DbwxDcztE9m1q1y5BkbKbN3GBkDGB0AAHaoJfCdxJ4ZfSYryztDKiRSvaaeI0dAw3ArvJ5UFfvcbicGunopttu7Ekla3Qw7rw69zdaxcG82y6lYpZqRF/qQofkfNzzIxxx/WoLjwtM2s3eoWOpfZnu9PSwkBg3GNUMhVoyGG0/vD1DDhfx6OikPY5eLwPaWlteW+nzfZ4ZNKTS7aPy8i2jXfkjkEli4J6fdFPXwdFH4ovNXjktj9qtoIfLktA7QGLdtaNi2FHzdMHkA+1dLRTu73FZGBqXhua/h1COPUBB9uu4J3Pk7sRx+Xuj+9yGEZGeg3ng1Hqvhe41GLU4Y9TFvFqFxDM+LfLbUCK0ZO4ZVgnoMbj1HFdHRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc348/wCRdtf+w1pX/pwt66Sub8ef8i7a/wDYa0r/ANOFvQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBm6p/yEdG/6/W/9J5q0qzdU/5COjf9frf+k81aVAHN+KP+Ri8Gf9hqT/033ldJXJeOLWa91Twjb21/cafK+tPtubZYzImLC7PAkVl5xjlTwex5qPVNPk0O0F1rXxM1XTrcsEE13/ZsSFj0G5rYDPB4oA7GiuE0qS0125a30T4tXmozKu5orSXS5WA9cLbE4qC81LSNOvJbTUPjJNa3MLbZIZ7nSkdD6FTb5BoA9Corio7dZtFOsQ/FHUpNMAJN6raYYQAcE+Z9m28EEde1RXRtbHTYdQvfixe29lOQIrmaXS0jkJBICsbbByATx6GgDuqK4UPaHR/7XHxZvDpu/wAv7b5ul+Tuzjbv+zbc57Zp+pRxaPbxXGr/ABV1CwhmO2OS6fTIlc4zgFrYA8HNAHb0VwOm3enaxerZ6R8X7m/unBKwWs+lSuwAycKtuTWufDmpiZYj4+14SMpZUMOn5IGMkD7L0GR+YoA6eiuJuYY7LV4dKvPinqFvqM4Bis5X0xZpMnA2obbcckHoO1FxFFaX81ld/FTUILuCE3E1vK+mLJHEBkuym2yFA5yeKAO2orzca7oDMAvxsJJOABe6Tz/5L10TeGdVRC7+PdfVVGSxh08AD1/49aAOmoriLaKK90uXUrP4qahcWEIZpLqJ9MaJAv3iXFtgY788VHpctnrlybfRfi3eajOq7jFaTaXKwHrhbcnFAHd0V5xJrehRSNHL8amR0JVla80kFSOoI+z1tw6Pd3GnLfwfEbWZbN4/NW5RNOMbJjO4MLbGMd6Olw62OsoribKKLUrCS+074qahd2kQZpLiB9MeNAoyxLC2wMDr6VQXWNEa3edfjQ5hjZVeQXek7VJzgE/Z+Cdpx9D6UAei0V5/p97pmrXqWelfGC4vbqTJSC2uNKkdsDJwq25JwATWhNpsttqUOnXHxL1aK+nUvDauNNWWRR1KqbbJA9RQB2FFc0PDGrMoK+PNfIIyCINP5/8AJWl/4RfV/wDoe/EH/fjT/wD5FoA6Siub/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+RaAOkorm/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWgDpKK5v/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FoA6Siub/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+RaAOkorm/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWgDpKK5v/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FoA6Siub/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+RaAOkorm/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWgDpK5vx5/wAi7a/9hrSv/Thb0f8ACL6v/wBD34g/78af/wDItc/408OapDoNs0njTXJwdW01QkkNiACb6ABvltgcqSGHbIGQRkEA9Eorm/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWgDpKK5v/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FoA6Siub/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+RaAOkorm/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWgDpKK5v/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FoA6Siub/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+RaAOkorm/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWgDpKK5v/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FoA6Siub/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+RaAOkorm/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWgDpKK5v/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FoA6Siub/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+RaAOkorm/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWgDpKK5v/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FoA6Siub/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+RaAOkorm/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWgDpKK5v/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FoA6Siub/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+RaAOkorm/8AhF9X/wCh78Qf9+NP/wDkWj/hF9X/AOh78Qf9+NP/APkWgDpKK5v/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FoA0tU/5COjf9frf+k81aVcfc+HtTtta0OSbxhrV2i32TFNDZBWAhlJB2W6nBAKnB6E4wcEdhQBzfij/AJGLwZ/2GpP/AE33lTeOgG+HniIMAR/Zdzwf+uTVD4o/5GLwZ/2GpP8A033lZXxUtvEF/wCHYbHw74c/t9LiRlu7f+1GscR7SOWWRCwOSCuSD3FTJXTQ4uzueV+FF/4SNfhvofiMLoSafbx6hpV9FJ5n9pspGYdxVfLYdSvzZzwemeuv59Xtf2jtWk8P2FteT/8ACNxb0nuDFhfO6rhG3t0+U7QfWuWk8O+PJfDtnocvwhtHsLCf7RaI3iRi9u+OqSfaN6j/AGQcZ5xTpdF+I0uty6wfhhImozRCGS6i8YTRyMg6JlbkfLxnHTPNaSleV/Nv7yErRt6fgelePfCmoajZ6bP4KubS01XRr19Qgs5kBhun2ncrD+Enf97sW7ZyOT1DxJceIPhH8QIdc0D+wtetLVv7QtOGViYvklDY5yFx1P3RzVG2HxPtNPSzi+FVoUjaR0lk8QCSZGf7zCZpjIGOOobI7VBfWfxL1LQpNHvfhXDLZzNvnH/CTMJLg42/vZBcb5BjjDkjgegqGrxce5afvJ9joTpXiV/AXgbW/A8tnLqek6ShOmXYAS7ieKPcAeNrAqMHI69fXpfAGtp4j8L6heXGgf2FqUF1NDe2TKP3U2xckHA+8uw/j36155aw/E6y0mDTrX4WwxwW0bRQOPEp86FDjKpL5+9R8o4DAcCr0eo/FqHR5tMg+F1lDbThhJ5WuIkjlurGQTB9x/vZz71dSXM5Pvf8WTBcqiuxf/Zthjk+Dtk8kaM0d7cMjMoJQ5xkenBI/GqPxO1+fQfHXh7xpYzXj2Wn3x0y8XyZBbfZ5MB3342khwR16ovpWb4dsviV4T0q603w/wDCqCzs7oESQjxKXC5BBKbpzsJz1XB6c8Co7rTPiPe+FE8NXfwrjl0hG3C3bxQ/P+yW+0bmX/ZJKjjjihv3k10t/wAEEtGmen/ETwNY+P8ASorC4le3uoUe4sbyI4eCYFNrA+nqP64NZXww8S6n4ia+0rxnp4tvEWjxJbX6NHxKjElJAehDAHocZGehFcXptv8AFHSLmzmsPhmUaxjMUCP4skkRUJyVKNcFWH1B6D0GNlfEXxhS+kvU+FmlrcyxrHJMNUhDOqklQT5nIBY4+pqdEx7rU1NBRJf2jPGSSKro2k2YZWGQRjoRXXeONGbxB4NvtJi1L+zJboLHFccYD7gVUjuGICkdwcV5DZWXxL07xRN4itfhbGuqz8Szv4od/MH91la4KlR2UjA4wBgVtX+vfF/VLX7NqPwr0u4g3q5jk1WEgsrBlOPM7EA/hQ9Ypf1uNO0rmx4L8Ra/e+K7zRvH3hu203XINOZ4b60O6G9gDgNg84wSpxn+I8CvPfhP4K1Hxr8NfDAkltdP07R9Zkv0uYpGe5mZXOY9u0BF/wBrc2cDgVtwS/FW3iu0j+GELPeRtFLPJ4kMk2w/wrK05dF7gKQB2xTPCw+J/gvTXsPDfwqtLS0d9/kt4gEqq3cqJJm2574xmmnZ3/re4paq39bWNO0uNZtv2gvGX9h6dbXiSppaXhlmKNFEQAzqu0hyFLHBK9O/SneP0gPxU+Hfh5444vDpuJ3MStiKSdBlIyOnytjA/wBrFcwNB+Iiard6lF8MJYr29wLm4i8ZTo8oHQMRdDIHYdB2rR8v4lHw/b6LJ8INKmsbZi8KT6xHI0bklt4dpS4bJJ3Zz70oe7y+X9fgD1uu57c9hbNfxXpiT7RFE0SPtGQjEErn0yo/KvC/AiKP2dfiCAoA+06nxj0iFXrK++Len2UttB8NY2WVGRpZ/EpmmCnqBK85dfbDDB5FYNr4X8eWWi3ekWnwnWHT7x99xbJ4tlCSkgg5H2nuDyO+BnOBiZRvf0sVF2t63PQPhTJdS+AdFk8SWNnbWNhp1rJp90Ji+4sjozElV2NggFeRz1OaxfFra/4H1LXtctdMt/GHhPV5TLqlu5HnWRQbGA6hkAXpjjHbqeftNC+IdlHaxQ/CpWt7MYt7abxZLLDFwV4je5KjgntxWjcL8TbqZpJvhNYESSPJNEuuKsVwzdTLGJgkvtvDY7YrWo1OTl6kQ91W9D23TZ4brSrSe0LGCWFHiLDBKlQRn8Ks1j+FLrWbzwxaT+JtLi0nU2DiayhlWRYgHIXDKSDlQp698VsVL3BbBRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXN+PP+Rdtf8AsNaV/wCnC3rpK5vx5/yLtr/2GtK/9OFvQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBm6p/yEdG/6/W/9J5q0qzdU/wCQjo3/AF+t/wCk81aVAHN+KP8AkYvBn/Yak/8ATfeUz4i+Lf8AhB/AOp6+kInltowIY2ztaRmCrnHbJGaf4o/5GLwZ/wBhqT/033laev6HY+JfD97o+qxebaXkRikHGRnowz0IPIPYgVMrtaFRtfU5jRvCuqXfhWC+vPE+rLr95bLLJdx3J8mNmAbYtucxBR0yE3Y/iyasaj43vLLx1d+GLbRPts8WjHVLd47ra05D7PKKlcLz/Fk9uKytd+FUviTwPY+F9X1uO4trEx+VdtYA3O1MYBcvjJAwSF5rZi8EfZfiTD4os7yCC3i0r+zBp6WmAE8zzNwcOAOe22tHZy021/L/ADIjdR13t+qv+Bn+LfiYfCOoWyXuiTGya5gt57iSUxsDKMgxKVKzBTw2GBUkcHNQ6/8AE290XX/EumxaBHcpoOnJqLTG/wBnnRH7w2+WdrDDYHIOOSM1D4t+Er+K9X1S+m8QSQi9ms5YYmtRILYW+coDuGVcnJxjkDrVrXPhrcaxrfifUE1qKAeINKXTTGbIv5AAwXz5g3Hk8YHb05h3t9/5afiWrX18vz1/AseFPiI3iXxQ2j3GizaZ5umR6rZtNOrvLA7lPnVeEbIBwGbgjODxU3ifxrqGg+NtE8PWWiR351qKcwTG98ry3iXcQy7D8vK/MCT1+U4AMOgfD+50XxhZa7Lq8Vx9l0OPRzAtmU3qjbhJu8w4Oe2DXP8AxC1G2tvjh8PojqNpaTql7/x8MCF8yNVTK7gfmYFRyMkYFaNRc0ltr+tv0M483K2+3+X6l+z+L0Go6Fo8thpEjazqt/JpyabLcBFimi/1m+UKfkUYOQpJyOOuHH4w6Y+h6TfRWywS6hqEmnyRX1yIEt5Y87w0gVhnpt6A5GSvOGaZ8IY9Kt9Glt9ZL6npepXGo/aXtRsmecYdTGGBC4xj5u3erunfC+0sPAtz4amuYNQjvJZ57iW8sw4aWU/fVdw2le3JPvUdP68v+CXpf+vP/gFc+J9Tf4sCwa3ntynhhr9LN7weSZDIow6iM4cEFdwZhjoOTXA/8LK8Sa18P/Cut6grWaat4ljgWXTdQMTlfMceW6GIjZhcEBjuwM9SK9F0X4Zvoview1OPWmuIbTQhophnty0kih93meZv4Oe23pWKnwUkh8EeHvDkHiJRHoWrf2lFM9hlpcMzBCBIMffPI/IVWif9fzf5Eyu1p/Xu/wCZs2fj/WbrWPEGjyeHrKDU9ImgSKB9UbF2kp+Vwwh4GPY85BxjNMv/AIvaJp/jhfD8rQMPtsenvIt0vnLcOu4fucbjGMhTJnhiBg8kdA3g+yb4hJ4t3sLoWBsmix8rfPuV/wDeALL9GqHQvCD+H/FGu6lY6gPsetTLcyWbQcxTBcMyvu6MAOCvXvUx6X/r+txvrYueJdeuNDt7Y2mmS38tzIYwfmSGDCFt80gVvLTjG7B5IrjYPjbo83w/0vxHJbC2m1O7NjFa3NyscaTAkMXmIwsYxkvjpjjPFdL4x8HyeLLrQ5F1R7OHS75buW38rel1jorDcOh5zz9K5Cz+CEdj4U0fSodff7VournVLO8NoOpbOx03/MOBkgjp2pq3X+tv+D9wf1+f/ALlv8Ybe+fwydP0tbiHXLyexd1vATBNF2XCkSK3Zsjgg1cl+I9/Elvav4c8rWV0+XU9Q06e9Cm0t4225DqjB3Yj5VwoPOSvfQ8U+CbnxLr/AIa1T+1YrZtCu2ufL+yFxOSAMZ3jaOPfrTtd8DjVPEVzrVjfCzu7zSX0m43wearRM24MAGXDAk88jnpQ9vP/AIH+Yle/3fnr+Byl34ql1X4m+EdT8KXN1e2OraPdyrZtePFBKyY2F0OVUgsQSFJ+uBWfq3xPPiOD4f6jpK39hDqWui1uoYrwRsjqdpjkGwiRDuJ6jt36dZafDGLR7zw1PoWp/Zv+EfsZbOJJ7fzRMJMbmbDLzkZ47msqP4LRWml+FrLT9baMaBqjanJJNa+Y11IWDEcOuwcY79vxuPKpLsn/AO3P9BJOzvv/APa/5nRWXjmXVNdmh0fRZtQ0mC6kspdQt5gSk8ahmBjIHyZO3duzuBG3GCb3jHxXF4R0m3uGtzd3V5dx2VnbB9nnTSHCgtg7R1JODgDoaq+F/BT+E7zWV0zUv+Jfqd418ts8GXt5Xxvw+7BU4GBt49TVnxh4Uj8V2enp9q+yXGm38N/bTeXvAkjJwCuRkEEg4IqI292/lf8AUp7u3y/Q5HVvjPFpnhW91NdG8y80rVl0vUrNrvaIXJI3o+w71z0yFJGemMVtXvjvUrS+g0tvDvl6rf6hJa6bBcXmyO5ijjEjTmRUbYuONu0nPHuMDVvgoup+GdZ05de8q71rVxql1dNZ71BBJEapvBAGepY1P8Zb2703Q9Hmt7OxvJI7ks73N62n7DsI3Jc70ERyem8FhwMjNJtKK7/8N+tx2vLTbX9f+AW/D/xK1DxB4Ri1iHQbeKaa6lt1ja+kMEHlAl2nm8jEY+UgfKwJK8jJxBcfF5T4L8P+JNM0X7Xb6vqCafLC935clvKzFePkIcAq3OV7evFLwZp2peMtJ0S5v9Lh8M22gXrvHp9sy3NrqCmIbJFdWwdrMSGyw3AnOek8fwfng8D6R4ch8QR7dL1caotw9gSZCHZwhUSDH3jk9/QVaUebXy+7qRrbTz/X/gGF41+KdzqXwr8SXdpa3el3uj6wNNuTZahsddsgG+OTyzkHgEFRwTz6+g23jWKfxw3heGGN54LeKWZpLgLL84J3LGV+dAAAWB4LAYxkjkL34Iz33hfxPo7+JI1/4SHVhqbzDTz+4O7cUC+bzzjnI78enX6n4HXV9d0fVL26hE+k3CzQyw22ybaE2mLzN33GbLEEHrj3qVbS/wDWi/UqXW3n+en4HIJ8cJktb66u/Cz+RYa7/Ykotr4SO8nOGRWRQeRgglcZByeQNE/F9LPw/wCJr3WtGNld+HryO0ntluvMRjIVCN5mwYXLc/KcAcZqg3wVuTp+oWy+JIh9t8RDXSx04nYwJPl483kc9f0rpdE8Bz6RrnibUJtStrxPEFyk0lvJYfIiqpXYcyHcCD7f0pLb+vL/AIIdf68/+AdFoWqPrOlpetAkKycxmOcSpKuAQ6OOqnPB4OOoB4GjXM+BPBVv4F0e70+0umnjub2W7CbNkcG/H7uNcnagxwMnvXTU3boJX6hRRRSGFFFFABRRRQAUUUUAFc348/5F21/7DWlf+nC3rpK5vx5/yLtr/wBhrSv/AE4W9AHSUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGbqn/IR0b/AK/W/wDSeatKs3VP+Qjo3/X63/pPNWlQBzfij/kYvBn/AGGpP/TfeV0lc34o/wCRi8Gf9hqT/wBN95WnrGozafBCLW0nuZriVYlMURdYgTgu+Oigc+/T3AA4avbt4g/shMtcC3adyAcIAygDPTJ3Zx7e4om13SbaW7iuNUs4pLGLz7pHuFDQR/33GcqvB5PFcLp+h61pfibxKtrd6pqLf2MsdheX8Ma7rgtKzKHSNAeTGcnPU8nHGxPaKPAT2ei6Ncxu1oLRfMi2TL5hCyE55JA+Zj3IyCaPs3/rqP7Vv66F208daJqUto2majp9zaTW0t3NML6INBChx5hTOdpIYE8bSOcHitm01XTr9kFjf2tyZIVnQQzK+6M9HGDyp7HpXN39vqsusa1Pb2kqJBpK2unBQOZHyXPXHURDj+4faqN/4d1K3j1S30lJdltoyWVk4O1pGdiZSD0B2rGFxjBHYYpv+vx/4Al/X4f8E65te0hUvXbVbILp/wDx+MbhMW3Gf3nPycc84px1nS1WRm1K0AiCGQmdfkD/AHCeeN3b17VyWoadezvf3Gl6c1vZGwTSrKFISjkSuPMlZDjaqAjAIB4c9CM1Nb8NXjXeotYWUh/tK7tNOZwufLso13yP17lpVz6tn1pLt/X9fkHn/X9fmd9JfWkTSiW6hQw7fNDSAeXu+7u9M9s9aa+pWMWoxafJeW6XsyF47ZpVEjqOpC5yQM9a5ZdElb4l61Iloq2F/plos83lja8iSTZU+rFWXnsPwqpoFhrB8DXaX2nt/wAJODdzme4UHFw28RtG/QjayhcHheDjpR5jt0OyXVdPfUJ7FL+2a8t4xJNbiZTJEh6My5yAfU06w1Gy1WzS70u8t722f7k1vKsiN9GBINcbpGjrHokaz6ZfyxTWIspYzH5Jt0f/AFu2MkszHAZmJYsdu0noN/wgmpJ4djGtIRdrI6GV0CSTxqxWORwOA7Iqkj9B0DtuTrublFFFIYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc348/wCRdtf+w1pX/pwt66Sub8ef8i7a/wDYa0r/ANOFvQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBm6p/yEdG/6/W/9J5q0qzdU/5COjf9frf+k81aVAHN+KP+Ri8Gf9hqT/033ldJXN+KP+Ri8Gf9hqT/ANN95XSUAFFFFABRRRQAUhAZSGAIIwQe9LRQBFbWtvZWyW9nBHbwRqFSKJAqqB0AA4AqWiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArm/Hn/Iu2v/AGGtK/8AThb10lc348/5F21/7DWlf+nC3oA6SiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAzdU/5COjf9frf+k81aVZuqf8AIR0b/r9b/wBJ5q0qAOb8Uf8AIxeDP+w1J/6b7yukrm/FH/IxeDP+w1J/6b7yuhllSCF5ZmCRxqWZj0AHJNAD6K8Y8GeOLWb45ahA2uWd5beJNPiuLaO3uklW3mjyvk/KxAbZyfU1oeMPibr/AId1TxlFaw6bJB4ftrO5hEkEm6UTNhlYiQDjsQPwND0S8wWrsv6uer0V5x48+IOseFhqEtlbaeYLXTI7+ISlpZJj5m11KqwMagEYcgjJxz0qbWPiDqKeKLrRND09Z7m20ZNSWM28kzXEjsQsI2EBOn3zkZbpxyf1/X3B/X5f5noNFcOvivXr34jan4asYrGFYdHhv7drmFyyyO5UpJh+Rx2Ax71gat8Xb6xku7+2sraTSrTxImhOjqwlb5QXlDZxwxwF29B15o62/re35jtdX/ra/wCR6vRXiUms3vhLxl8WNb0aOzJsDp9xJBNExEq+SSwBVhtY5Jzg89q3LnxdFp3xI8RajJp9uVsfCsd+swDiZ0DM3lN8xXGc8hQeepxQ9Ffyv+Fwtrb+un+Z6jRXN+DtT13WdLtdU1Y6abO+sYLmAWiuro7jLK24kFQCuGBBPPArmvE/xI1LStV8Wxada2rQeF7K3uZhMjFrgy5YqGDALhR1w3NOS5XZij7yuj0miuFHjDWL/wCI914c0pbFYG0BNUtJp4nJEjOUCvhxleh4ANc94o+KHiPTNemstKs7D91r9tpAtp4JHmlSSLeZhiReOuBjHB59Czvb+t7fmK6av/W1/wAj1uivLfHPxQ1bwl4iWzitdOlhGp2lr5ZdnleKZCS52t+6IZSAGB3AZHSovGHxN1/w7qnjKK1h02SDw/bWdzCJIJN0ombDKxEgHHYgfgaRVne39dj1eivOb/XbqP4xS29ppdrc3EXhSS9tnCuJmYygeTndtKkqP4c571kXvxevH+E+peJ9Fk0+TUtNeGO6sLq0kje3kaTY6OnmZHXg55wePR20/rvYEruy/rS567RXl2u/EHxJpuseLbO2XSmTw/pEepI0lvJmYspJQ4k4+6efpx3q7ffE06frWiRamkOl6ZrWnRT2t/PE8kb3LnPkFlI2YXByRzntii1/69f8mTdf18v80eiUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXN+PP8AkXbX/sNaV/6cLeukrm/Hn/Iu2v8A2GtK/wDThb0AdJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZuqf8hHRv+v1v/SeatKs3VP+Qjo3/X63/pPNWlQBzfij/kYvBn/Yak/9N95Wh4h0V9f0o2K6rf6WrOGeWwaMOwH8JLow2nvgc4x0yDn+KP8AkYvBn/Yak/8ATfeV0FxJ5NrLJuC7ELbmGQMDrjvSY0cn4v8AhzZ+M7nSLjUNa1a1m0hxLbSWbQo3mcfvCTETngcDC+1UNf8AhDpviK+1q5vde1qP+244YryOFrcKyRcoozCSOeeuau+HPF9/L4JuNS8UwW1vqlrPcQSW9sGVWeMsVVQxJ+4ASe3J4Aq14e8S3TeGLC78V+VBqV3bfa2tLO1lYwxnHBUF24yAW4Gewp2ur/1qLZ/10KepfC3RdYe+k1O61C4lv9LTTLmQyIpdEOVkwEAD554G3j7tXpvA1jJr2m61BfX9rqNjbfZGuIHQG7g6+XKChBGecgKQTwRUep6+i+ItJmtdWlXTRYT39zHbQrMk8Q2BGOEZwPnJBUjO05zWrHrlndX0EVrfRtHJZm8GIWIeIldrrJ90DnpyTkdMHL21/rr/AMEW+n9dP+AU4fB1rb+PrjxZHf3ouri0Wze1zH5HlryABs3Zzk53d/Tiql98ONC1HxCNUuvtDJ9rS/awDKLd7pF2rOV27i23jG7acZIJ5pnhrWbz+xdHGqanLPc3qTXhNzY7pJbYElRmJURGCtHk7TnoBk5rc07xFpeqpbPYXJkS6tzcwsYnQPGNuWywGPvrweeaLOPyC6Zh6j8NNE1PWdQ1Caa+T+1ZIn1K2jmAivREAI1cEEhRjopXOTuyOKsyeBNOm8YX/iGe5u5X1CwGnT2T+WbdofTGzd3J+93Pbirg8XaI1tJcLe7oY4Dc+YIXKvEOrqdvzrx1XNT3XiLSrOS5S5uxGbWGOebKN8qSMyp25JKkBRz7cilbT+vQd3cq+EvCdr4N0VNK068vrm0hZvs6XkofyEJzsUgA7R2zkj1qlr3w80fxDqk17dyXUP2uOKK/gt3VY75I23IsuVJwCT90qSODkcV0tvcx3UZeHdgNtIdGQg/QgGpaN9QWmxzi+DLVPiAfF0eoXyXbWYsWtVMXkNCDuC42bh8x3ZDdfbiuM1bQPGp8aapq2ieIJbFjOGtdPn0SK5WdFRRj7V1jRip+XIK8nqa9Woo63DocPrnwm8P6/qF/e3k19HcX15bXrtDMoEcsC7UKgqcZBIIOevGKg8QfCLTPEeoa3dXmu61F/bkcUV5FA1uEKRcoozCSMHnrk+td/RQO7RyQ+H1t/wAJVD4gk1vVnvI9M/sxxvhVZYepztjBDbvmypXkcYHFVtb+Fula/pOq2V9qWpBtXmikvLqMwrLKsX+riz5eNq9em492OTntqKbbf9fMS02OFvvhXY6hda1cXOvayZdbsI7C8ZWtxmNABx+54JAbJ/2jgDjFyX4daddaPY6Xe6lqV1aWiwo0Uske24WEkxhwEAGCRkoFYgAEkV11FFxWQUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXN+PP+Rdtf+w1pX/pwt66Sub8ef8AIu2v/Ya0r/04W9AHSUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGbqn/ACEdG/6/W/8ASeatKs3VP+Qjo3/X63/pPNWlQBzfij/kYvBn/Yak/wDTfeVd8SR6zPpv2fQbaxneY7JjeXTwhYz127Y3ySMjnGOvPSqXij/kYvBn/Yak/wDTfeV0UjFImZUaQqCQi4y3sMkD8zQBxOv+Ftea31pdA/s+4bV5Tlb2d4Vt42jRJNu2NyzNtPXAHHXkG5eeHNVk1zU7myks4otWsYrWaZnYyWmwOMRqFw4PmMQSVwR0OcCHRPiVp+sLYSz6XqWl22pXDWtlcXoh2TzKWBjHlyuQfkbBIAOOCeK7Ki1lYL6+Zxy+Ebu1vr6105LSDTbvT4bBLgyuZoIo1ZRGse3B++7b9/Uj5TjmaXwtdJJrxshaxLd6fFp9gu9gIokRhg4X5fmdumcjHpXV1FdTG2tJZ1hknMaFhFEAXfAzhQSBk/Wm5N3uJJK1jntQ0LVrrVtQmhmtUt20j7FZAMytHKxYyMQBwvEWMEn5TxUNz4Pmd9Rgs5orWyfRRptiFyWhYl97EY7/ALvvk7a6yil0t/X9aj/r8v8AI5fVdM8Qaz4POnywaZZXUskSSwQ3MkkXkCRfMUSeWpyyAgDZgZxz1p0mh6iBrreTYXp1KT/VXEjoskYiVAhIU7ACGPAbr6ni5r2vXGk6dqdxb6eZWsbdZ1a5l8mGfJOUVwHO4bem3qyjucbEZZo1MihHIBZQc4PpnvR3DZIo6BYXWleHrGw1C9a/ubaBY5bpxgykDG48mtCiobi8t7RoVuJVjaeQRRKersewHfgE/QE9qbbbuJaImooqG7nNraSzrBLcGNSwihALv7AEgZ/GkMmooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5vx5/yLtr/2GtK/9OFvXSVzfjz/AJF21/7DWlf+nC3oA6SiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAzdU/wCQjo3/AF+t/wCk81aVZuqf8hHRv+v1v/SeatKgDm/FH/IxeDP+w1J/6b7yrfizUZdO8MX0lrBdXF08DpbpbW8kzGQqQvCAkDOOaqeKP+Ri8Gf9hqT/ANN95XSUnqhrRnG2vg2y0LRYrhHvNWXSrIjTbG5iQpbkR4+RFQMXYcZfc3JAIyc4kng+58OeF/DtlZwySTNPFBrF5ZwkyfZ/mlkUKuTtaQAHAJw7HvXptFXzNu7/AK/rqSlZW/r+keXa9YiWRrP7BPb2GsazAscEVmxaKCCPfJMI1Uld7LszgHBB71Z1bR576cRQaXNHZ6zrcLSqbbi3t4I9zSFcfIZGj2ZODhx34rtpdBsZ/EEGtSG6+2wRmKPbezLEFPUGIP5ZzxyVzwPQY0qSsv69P8h6/wBfP/M841Gx1TVWvIm0iRtWudZRUupIsJZWcbriRJDxyik7VOd8hyBzhbzR7zWLqB1sZraK+8RLcSk25Uww23RzkZBkaFOTjKvx3z6NRSjpZ9v+B/kNu97f1v8A5nmlzZTawzPPpl5ZWmoa8Zr7FnJ5jQWwCxggDJEjxq2cY2s1XYdLmk1bMtneWWlahqMl29rFAcOI4o40WRVHyrIwaQg4ztAbqRXfUULT+vT/ACE9f69f8zzXTba8mh0+TUdNv9Psr3Vrq5u7SGCRiAn7uCN1VSfLZVVjwF4A6HB2LrRLWPWLT+ztFylnbXd3bpLCSguHZdgBIITOGIGRgEcCuyoo9A66nmOk6TeHwT/aF9Dd3muSaZNE/m6dIkjXExG4Sb8lgGwBgBFUHtjF7WfBdnBJoOm2Onl0murf7ddrCW2QWoZ4144UFiE/3WI5r0Ciq5tbitoecXVjfahqbQw2N3b22oeIUe6doHGLe2QFe3KyPEPm6EPTY9Auda1bTtSms7iwj/tW61SRPIKMFjTyIkIxlWkVg5HU4PpXpNFStLW3/wCG/wAhvXTp/wAP/mcj4Jt9R034efabq0dNSuvPv3syhUxySs0giwemNwX8KzNP0mQXmkXgsru8vrWwubx7y7gaNprxgAFbcMrgPIAD90HA6V6DRTv20Dfc4HT9NQ+AGuGsr6612XT5Ip5rq1kWWSaXG4MGAyoc8cYVV4wKraxpWsaWusyaBbSs1vplvYW7pE25gzkyyLjltiFdqg8FSBzXo9FDd3cFp/X9djz7U/Buk6ppmpW9x/aVmmox26tPpto8G1Ym3KoQZbdljksOR/u8dP4ShePw/C9xYLY3MhPnRqmwMV+QPt/h3Kqnb2zg85raoouGugUUUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5vx5/yLtr/wBhrSv/AE4W9dJXN+PP+Rdtf+w1pX/pwt6AOkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM3VP+Qjo3/X63/pPNWlWbqn/ACEdG/6/W/8ASeatKgDm/FH/ACMXgz/sNSf+m+8rpK5LxxdTWWqeEbi2sLjUJU1p9ttbNGsj5sLscGRlXjOeWHA7nirP/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAdJRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAdJRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAdJRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAdJRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAdJRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAdJRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lc348/5F21/wCw1pX/AKcLej/hKNX/AOhE8Qf9/wDT/wD5Krn/ABp4j1SbQbZZPBeuQAatprB5JrEgkX0BC/Lck5YgKO2SMkDJAB6JRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAdJRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAdJRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAdJRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAdJRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAdJRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAdJRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQBpap/wAhHRv+v1v/AEnmrSrj7nxDqdzrWhxzeD9atEa+wZZprIqoMMoJOy4Y4AJY4HQHGTgHsKAOb8Uf8jF4M/7DUn/pvvK6Sub8Uf8AIxeDP+w1J/6b7ys74oeN7XwX4bR7i6s7eW+doI2vHnRQNp3EGGKRtw4xkAe/GCDIfDXjq41f4oa54eukWO0S0hvNKfGDPD9yRx6gv09qyPGPirxL8PvFkWsXd1Nq3g+4mFveRPBGG0wttIkDIgLJ8xGGz065IrzDXvGngqDxZ4b1/wAEeJ4ILrSwRcjVLzVZxLGcAwLvhfCdeRjr92u8t/jx4Ev7jVbXxDqum/2XdDbGIYbyZpFKhSJEa2UDIHYnrj3p9E1uhdX2Z3Vtpep6nBPLY+ONSa3muFlhmigs32wlM7EPk4IJcHcQxwox3J5P4ZXninxZDrF1qPjHUP8AiV67NYrELS02Swx7eGxCG3EE8gge1Yvgn4pfC7wF4Vl0XS/FrXkUc0stqLiyulIDchGYRHgHjIB45x2rG+F/xW8KeDoNdh1vxHpbpqOozajE1nHeuVeTH7tg1svAx94flS6/L/L/AIIO7X9eZ2PhXVPE+o3fj+1vvFl9L/Ykxt7GT7LaKyYXfvOIcM3GORjBPGcEc78P/iR4t1iz8KTQauPEt7qdy8Ws2BghH9nQiQqJsxIpj+UZ/eZDdqxPDnxT0HSJ/Glzda7oby+IZDPAkZvysTldm1ibMcYJOQOoxjnI2fhX8WfBHgn4c2nh/WfE1lLdWbS+W9rbXjpIrOXBJa3UqcsRjB6Z74Dg0ld9l+WoPVWXd/d0O6+I3xAu/BniLwykMIfTLm+W31SUjiJZARHz25DNx/cx3qj8bPEuteE7Lw/faLr0ulRXeqR2V3+6gZPKYMS+ZEbaQF65x6ivOPFHj3wL4z8I6smu67bDXLyQ+RHBfaqtlGAAI3KeQFLLjp5Z3EdRnjP8TfEew8T+EfC+m3/inQXv9Evorue5I1DFz5QwvH2TILZOT6jvnhLbXv8A19wn5dj2jwZ4g1XUPG2o6fb6sfEnhqO0SWHWikXFxuw0IkhVY3wOeBkdCak8T+Prjw38TPD2k3NuF0XU99pJdk/dum2mNfUcYHofM/2a8v0/4qeFfDPjS/1nw1r+k/2frMKSX2lTJfRJBdAYMkTLasGB75VSetYnjDxf4M8WeD187xNbx+KGvRc+eb3VGtIGByHjiNuVBxhdoQEDncT1e1m/n/X9dB90e1fEXxmvhXVdHt9T1G70TSL7zFk1a1t0l8uYFdkbb0cKrDeSdpPHBGCawPib4u13S/hvbeIfC/iiFt+opDFdWMEMkVxC/HIcP8ykHkEc546AZf8Awvrw1c6Up1TWdDurhrfyriwaC+NvK277wkNsSox1Uo3XGeMnhPEfiTwPL8O/+EZ8M+J9LhE+rtqcqzW19FFbDIIiiAgcke5x9OcCf8/1/wAv6uPz/rb/ADPXfipP4l8H/Dy/1/SfF+pfaLKOFESS1s2WQmQKzP8AuckkN/DtHA465u+ILbxFo/w61fWbfxnqklzb6cbyEy2tnlHSNmKnEABRsrkYyNvDcmvPPiT8XvCvjf4bS6DZ6/pVtfXuz7S0q3xih2uG+Rha5fO3HIXrVvXvjb4W1f4Y3OiR63pMeqXlo9lLuF95EashXer/AGXcx6HaVHU/NxyO/LLuVG14/j+H/BNe0+IWv2nhnwFYJeJqWveLSHkuryJFFtHtUuypGqA43cA+hzmvSdP07V9OuLdJ9buNVtzu89ryGFZAcfLgxIg25zxtJ5HPBz8+QeMfA0/hnwd9q8ZWdjr3hJh9mlt7G8nhuUAUFXJhRl3bewOPevQtK/aH8FzJv1zXbGzccCKzhvLgN772t48d+Np+tay5bu3d/d0Mleyv2X39T0vW799N0W6uYEElwqFbeIn/AFsp4RPxYgfjXJfDHx1L4m+Fseu64Qt7YrLFqOF2kSRZ3ErgYJXDYHTNcb4h+NPgDXtbsIJ9ejOiwZleaCfUbS6WbBAKiKAZABIwZBnd0+UZ5jwj8QfBPhjxl4j2eIbE+F9cOWt3k1G4njYKQZP3lv8AMXz8wLcf3jjnNXs1/Wn9fkXpoz1H4fa7rfxI8OxeKJdTn0W1mmlS3sLKOFwUVtuZHkjYlsg/d2j2NamuWfiVdAvr2TxJPYTWMdxIn2C1g2zgDMZYSpIRgDBwRkknjgDyrwX8VfBvw80dPD+jeJ7DVtJjlkkhmvIby3nhDHOwqts6vzn5sr16V0fiD48eB7zwne2Wn+JLO4v7mF4R59peQRKGBBORC54B6Y5x2pTvyvl7BG3N73c3fhyPEXibwDpmu6l4w1Jp9Rsy0iLa2YWJy3DR4h4Ix0bcOTx0ridH8Q/EXXfgfqnifTPFF1NrVndyBIhY2pR4YyAwC+VnOCW+oApvgH4z+FfCXw3ttDvdd0qe/wBPi8q3MK3winGc5dja5Tr2VulVvhJ8UvBfgjwncaN4g8TafITdSTxyWVveSBg5yQwa3XGPxznt3qVnKVvl95nDmUY3+f3HqGnX134q0Dwvc6P4mvrc3VsLi5lhht3M6BBu37oiqtvIHyhercccYfh3UPE+p/Fbxl4em8V3hs9LgiNnutLXKNMhO4kRAttPQd8c5rlfht8Rvhn4B0/U7RvGhuorm/kmtkFhdbbeEnKRjMfXkk44yao+F/ix4W0v4qeIvEmp+IdKFjrSRIEt0vnlh8pdqnBtVDbu/Ix70Ozl5WZa0i776fmdnDN4ol+Mt34Q/wCE21YWUOjLfpN9lsfM8wyBME/Z8bcdsZ96n8Sa3r/gr4leH5tY8RXUvhPUy9vP5ltbqkFztOwM4j3BGPI5yCDk44rhbH4s+F0+Ndz4uuvEGkpps2n/ANneXGt88wQPvWTBtQuTgArnjP3jjmT4v/FPwZ488Ft4f0LxJpyefIsklxewXsflbGBG1Vt23Z5BORj3zwtlF/f97/QN21/W3+Z7VocWozanqGoXWp3U+nzybbK0ljiCxoOrgrGrYJzgMzcYOeeNyvPvh78VvDHitbPRLLU7aXWFgO63tY7ho9qDGQ8kMfbBxgenPWvQab00EtdWFFFFIYUUUUAFFFFABRRRQAUUUUAFc348/wCRdtf+w1pX/pwt66Sub8ef8i7a/wDYa0r/ANOFvQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBm6p/yEdG/6/W/9J5q0qzdU/5COjf9frf+k81aVAHN+KP+Ri8Gf9hqT/033lbOo2Nte2xFzZW140YLRpcqCu7HqQcfXBrG8Uf8jF4M/wCw1J/6b7yrPjC6ubfwrfrYW1zcXc8LQwJbRl2DMMBuOgGc5Pp60nsNbnGaFqlxq+n6dqlx8P8Aw/baZdyHzJlvg8kEILDzypt1BQhcj5uhB45x1tpB4Nv4Y5rGLQrmKSJpkeFYXV41OGcEdVB4J6A1R0+2s9I+2J4V0aeEjTQoZrRoEZogwjQBgCWO8847VWsdCvdAK2tlDNdf2TobpBcsB/pNxIeR16jyU/7761btrYlXf9f13/Av2E/gXU9Jk1SxXQptPilMTXapD5QYYyN3TuKlQeCJGKxjQHYRySkL5JISNtsjfRWBBPQHg1j2ulXuhpBZ2ely3VtpWihNOLgHzLnLCRm5+ViFjIPUh275FVofDl7p+gjSrKylZNN0L7NauRjz7mYkO3XqpRWP+/6ik1vb+t/8vxGun9dv8/wOsi0rwxPcGCCw0mSYRrKY0hiLBGztbAGcHBwehxTLTTvCt/JPHY2ej3L2z+XOsMUTmJsZ2sAODg5wa5e+8L6laxavFo8coig061060UHBeINunZTn7xVtoHYoOnFJ4i0jXLuLU9Q8PWotoPs9tY29qISkkluJd87BMqR8rFVU4PDdNwpPR/1/X9eQLVG1qI8LR6Hqt5pdpol1LpsbmVY4IpfLcLuCMF5BPHBI61b06x8MX+ntcRWmiTiHKXElvHE6RyKPnUkdMeh5FYOq+HmnFsPIuHsrm/glv5vIO+SCFd8cIiVQVTzMDBHQuT1zTpNHvLjXYdRv7G6itb/UPPuLRCHwIodkCyBcjBI3HnAIQE8U7f1/X5CudBYaf4U1SHztMs9GvIsA77eKKReQCOQD1BB+hqlFa6CuvXVle6bosMfmxwWm+3jR5pTHvdAD94hcHjsTxxmrPhGK9FlqF3qtn9ju7zUJpWiH91SI0Oe+UjU59657T/DuoajcaRf6zBMkr6nPq08eBmMqCkEJ9grBvqlC31G1ZGpbzeEZn1CWS08Px2NlcLbfaxJbsplIG5Gx9xgxA2nk1PMfBUGt2ujyQ6INRu1Lw2uyHzHUZywXqRwRx6H0OObTTtT1LwrDe6lp97ba61/JqltsTd5U4JWKFxz8piwjE4GM8jg1r6rpWpyXevf2ZA0Cx6KtnpqxAIqsd5fYex/1YHTGyl0u/wCtP8x6Xt/W/wDka9vp3hW7vLi0tbPR5rm1IE8McUTPCT03KBlc+9UNBg0DUtOee507RwQ8xQraJHviRynmbTkhTjrnHSoPsV3595eaPp5tLKx0mS10+HyzHJNK+GY7CAVAKIBnkksemCX/ANh/2druhR6ZpyrHHpk9jLIoX91HmHZuPf7h455/E0W/r+v61Jv/AF/X9aE883ga21A2M40GO5Fq140biEFYRyZDnouOc9MAntUGnTeGJfDNlrGt6boOlJdnCb5beSNiWITbKPlbcMEY9cVDqGlXVkviOfTLKcyvZQabYxxDCpEqnDL9GmbOP+ef0qfTdO+yeJL+OfSZ2tjZW9tYxsoaFIQpDp1KqdxO7+8AuN2KrQNf6/r1NK70/wAKaeyrf2ejWzOrOomiiQsqjLEZHQDkntVr/hHND/6A2n/+Aqf4VyWs2Gq3/n2zaYzNfa3ElzNsyEs4yrLtPcMExjoGds139StVcp6Oxm/8I5of/QG0/wD8BU/wo/4RzQ/+gNp//gKn+FaVFAjN/wCEc0P/AKA2n/8AgKn+FH/COaH/ANAbT/8AwFT/AArSooAzf+Ec0P8A6A2n/wDgKn+FH/COaH/0BtP/APAVP8K0qKAM3/hHND/6A2n/APgKn+FH/COaH/0BtP8A/AVP8K0qKAKdto+mWU3nWenWlvKBjfFAqtj6gVcoooAKKKKACiiigAooooAKKKKACiiigArm/Hn/ACLtr/2GtK/9OFvXSVzfjz/kXbX/ALDWlf8Apwt6AOkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM3VP+Qjo3/X63/pPNWlWbqn/IR0b/r9b/0nmrSoA5vxR/yMXgz/ALDUn/pvvK6Sub8Uf8jF4M/7DUn/AKb7yp/G0l7F4I1ZtMDG5+zMAUOGVTwzLjuFyR7ik9ENauxam8SaRbtL519GqQtslm5MUTf3WkxtVuRwSDzVtL+1fUpdPSZTdxRLNJF/EqMWCt9CVb8q5fXNUOmWXh7TPCVrYXNrqtyLVYwuYkg2MzygqQMKq9O5Ycis2TXGi1u9bSr+V31jV00uIyXLPFaiKFmllRGYqrZSVcAAFkGQcHNWd7f10/zFfS/9f1oehUV5XqgbypLPRtQ1e5kutbt7GyH9p3AMSIm+aQt5mWABmyGJB2qMHC1qahcyWV9rOl3utalLFYWv9qSSCYRyytL5myFCgBCL5LHA5ORkkBsrpdf1sP8Ar9DrYPEel3DQqlyUae5e0iSWJ42eVASygMAeApOenBrTrzTTWHh1bRDezXF7pOhz6lfIly6xXE0zFwWQHacsJiDgkADnFbmkCWPx01lLq11fT29gbi9DSEReZLIAm1M7VAETgAZx1JJJJdraf1/WhO+v9f1qdPc6ha2dxawXU6xy3chigVusjhSxA/BSfwqxXH+IL63/AOErlH2q6U6Zo09zcQQ3kkSuH4jBVWA3YSUhvvDAwRVDR5rvSGS11a9uppdM8PmbUBJdSP8AMxG35ixJYeVL83J564xS6X/rr/kPW9v66f5nfAgk4IODg+1LXk+mRahpdnp/hKKTUJZW019T1C9bUmQPKzbWQzMxkVVOSfL+YHbkjJ3b1vb31r4i0ezuvEV7eRtZrbiVDtPnxESSeanIPmRkDJGU28EF8l2/r8xXOzur22sreae6mSKKBPMlZj9xfU+3BqevJY1TUba2u9NvNSjn8QeIGdJF1a52xWsJbLgeZjayJwv3f3qcEKoGhe3V3d3Sf2Pe3iLeeJkSBxeSsojh2m4PLYEeY5UCfdy3TJFJJu39dv8AP8CnZX/rv/kelVmLqGkWFxqMSeXbPaILq8IhKKFfcd5bGGJ2tnBJ45rhZtXvPE02i3VlqF3ZtqOrGPyYLgqsVnBIxYsAQMyNEqknkCTaO+ZdX1NNW01GsJriKbWNfEFvNb3MtuUihG2SQsjDcoSKRgD8pLLkGml/X3f18hPT+vX/ACPSOvSiuT0q6N547u3W9mntpraO6s3huS0EkWPLKGPOFZXy24Abt4znZx1lIPIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArm/Hn/ACLtr/2GtK/9OFvXSVzfjz/kXbX/ALDWlf8Apwt6AOkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM3VP+Qjo3/X63/pPNWlWbqn/IR0b/r9b/0nmrSoA5vxR/yMXgz/ALDUn/pvvK6Sub8Uf8jF4M/7DUn/AKb7yuguII7q2kgnUNFIpR1IyGU9QfqKAI4dOsra4ee3s7eKaT78kcSqzfUgZNKbC0aLy2tYDGZPN2GMY35zux655zXAaTaaHc+HNf8AFEGl2Kxx3s1zZyfZVIC2wCIwAwcF4S3BGc+9XdV1fxHDp1hDqFtpU0mrTWtolm9q7Fi243BZS+AoRS4GTjaQck00rrTy/EHo7Pz/AAO1W3hV96wxhtxbcFGcnqfqar29xpmpyTvaS2l48DNaztEyyGNhjdGxHQ9Mqax9K16+8Qquo6MbI6QLySBnmDb5I48q0iEHH+sUgAjp82e1Ynh7xVczRxao0SLYam97fyM6tuW2iCrHIvPQqI+Mc5JFIHod0baBpHdoIy8ibHYoMsvPyn1HJ496IbW3t2zBBFEdoTKIB8ozgcdhk8e9ctZeJ9Vc6VLqdrBapqVpNdNAFLPZoihgztuw33lBAA5brWbZ+N9bOnq+o2tpDcR6I+qXS+Uy+QSf3YI3kndtcY6/LnPam01v/W/+QK0tv62/zR3bW0DyO7QRs8ihHYoMso6AnuOTx70rW8LM7NEhaRdjkqPmXng+o5PHvXKz+J9UEOoAQW9o+k6bHdXssyGRPOZC5iUBgRtC5J5+8vvUV34t1WP+1HS1ggSy0mG7CzRsStzIHxATuAJ4Xpg/NQ01cSadv67f5nWyWdtM8Ty28TtCcxMyAmP6en4UotoFuDcLDGJmXaZAg3EZzjPXGa5vXPEmoWNvqs1mtnGmnokSm4DN9ounAKxDBGBl4xnnJfGBirn9qamfFz6W6W8Nv5KTRO8bE3C9JdrBsAqSg2kdGByelA+lzXSztoxGEtoVERJjxGBsz1x6Uq2sCBAkEaiMlkwgG0nqR6Zyawte1+50XxNoFs32c2GqTyW0hZT5kcgieRSDnGDsIxj8aqz+ItVtrW/EwtBNpdo11dTGBxG+SxjjUb8qxRctknG4cHNGtrhu7HTJZ20b747eJW3F9yoAdx6n6n1pBZWqiMLbQgRMXjAjHyMepHoeT+dchd+JPE1rPJZvp0f2qHS4rlTFZyzJd3Lbt0S7W/dqCqjLE/fHpzNqOt3tpqWo71sZZtJ0c3LTm0bKSyE7UB3k4Ii5Uc/dOelDVhLU6yO3hhkd4YY43kxvZVALY4GT3p0kiRRtJK6oiAszMcBQOpJrlJPFl7Z6hqUd9bReVZWNvIoVSrNcyu6rDnJGThOMcbxyetE3iLVLW/1u2ufskkem6ak/nQoybriTftj5Y9AgPqd69O6dxo6Ww1Cz1SxjvdMu4Ly1lBMc9vKJEcZxwwJB5BqxXH2qyaVqEWh6XBa3kuj6N5qmWM+aJmO1P3meBJskzxnjOa2fDOqya1o63kssbsWKMi27QtE68OjIxJDBgR+FNpdBK9tTXooopDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACub8ef8i7a/wDYa0r/ANOFvXSVzfjz/kXbX/sNaV/6cLegDpKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDN1T/kI6N/1+t/6TzVpVm6p/yEdG/wCv1v8A0nmrSoA5vxR/yMXgz/sNSf8ApvvK3L6yh1Gxms7kyiKZSj+TM8T49nQhh9QRWH4o/wCRi8Gf9hqT/wBN95XSUbgYlh4Q0XTPDaaBaW8w0yNgVgku5ZNuGDBQzMW25A+XOOoxgmr93pVnfX1nd3UReeyZmgbew2Fhg8A4PHrmrlFF9bh0sZNp4Z0mw+2CztnhjvCxliWeTy1LZ3FE3bYyckkoFyTk81ZGjaeskbC1T93bG1VTnaIjjK7emOB2q7RQBj2nhXR7KzubWG2cx3MTQyGW4kkfyz/yzDsxZUGThQQB2Aqe60DTLz7Z9otQ5vlRLgh2BdU+6Mg8AZPA9T61o0UAZdz4b0m81L7dc2gkmKqrKXby5NpypaPOxiMcEgkdiKkvNC06/hmiurfek9xHcyASMu6SPZsPB7eWnHQ45HJrQooAyLzwro9/PNLd2rSNNPFcuPPkC+bEVKOFDYB+Vc4A3YAOasW+iWFrqj6hDE4uHUrkzOyrubcxVCdqljySACcDOcCr9FAFW702zv5rWW9to53s5fOgLjPlvtK7h74Yj8aq3nhrSr+4u5rq2Z3vIVhnHnOFdRnB2g4DDONwG7HGcVqUUAcZqvhTUdS12aVo7ZEYgwapb381tdW6gfLH5aLiRActhn2kscrXQXHhzS7qa5lntmZ7qWGaY+a43vEVKHAOABsXgcHHOa06KA63M680DTL+G8iu7bzFvXR5v3jAllACspBypG1SCuCCAevNRy+GtJnjuY5bUlbqSKWb9843tHt2HOf9hc+uOc1q0UAZkvh3S5rq7uZLY+deCMTOJXGdg+QjB+UjOQVwc4PUCrGm6ZaaRYraWEbJEpLEvI0jMx5LM7EszHuSSTVuigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5vx5/yLtr/2GtK/9OFvXSVzfjz/AJF21/7DWlf+nC3oA6SiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAzdU/wCQjo3/AF+t/wCk81aVZuqf8hHRv+v1v/SeatKgDm/FH/IxeDP+w1J/6b7yukqte6bY6kkaajZ292sT+ZGs8SuEbBXcMjg4Zhn0J9arf8I5of8A0BtP/wDAVP8ACgDSorN/4RzQ/wDoDaf/AOAqf4Uf8I5of/QG0/8A8BU/woA0qKzf+Ec0P/oDaf8A+Aqf4Uf8I5of/QG0/wD8BU/woA0qKzf+Ec0P/oDaf/4Cp/hR/wAI5of/AEBtP/8AAVP8KANKis3/AIRzQ/8AoDaf/wCAqf4Uf8I5of8A0BtP/wDAVP8ACgDSorN/4RzQ/wDoDaf/AOAqf4Uf8I5of/QG0/8A8BU/woA0qKzf+Ec0P/oDaf8A+Aqf4Uf8I5of/QG0/wD8BU/woA0qKzf+Ec0P/oDaf/4Cp/hR/wAI5of/AEBtP/8AAVP8KANKis3/AIRzQ/8AoDaf/wCAqf4Uf8I5of8A0BtP/wDAVP8ACgDSorN/4RzQ/wDoDaf/AOAqf4Uf8I5of/QG0/8A8BU/woA0qKzf+Ec0P/oDaf8A+Aqf4Uf8I5of/QG0/wD8BU/woA0qKzf+Ec0P/oDaf/4Cp/hR/wAI5of/AEBtP/8AAVP8KANKis3/AIRzQ/8AoDaf/wCAqf4Uf8I5of8A0BtP/wDAVP8ACgDSorN/4RzQ/wDoDaf/AOAqf4Uf8I5of/QG0/8A8BU/woA0qKzf+Ec0P/oDaf8A+Aqf4Uf8I5of/QG0/wD8BU/woA0qKzf+Ec0P/oDaf/4Cp/hR/wAI5of/AEBtP/8AAVP8KANKis3/AIRzQ/8AoDaf/wCAqf4Uf8I5of8A0BtP/wDAVP8ACgDSorN/4RzQ/wDoDaf/AOAqf4Uf8I5of/QG0/8A8BU/woA0qKzf+Ec0P/oDaf8A+Aqf4Uf8I5of/QG0/wD8BU/woA0qKzf+Ec0P/oDaf/4Cp/hR/wAI5of/AEBtP/8AAVP8KANKub8ef8i7a/8AYa0r/wBOFvWl/wAI5of/AEBtP/8AAVP8KbJ4X0CVQsuh6a6hgwDWkZGQcg9OoIB/CgDUorN/4RzQ/wDoDaf/AOAqf4Uf8I5of/QG0/8A8BU/woA0qKzf+Ec0P/oDaf8A+Aqf4Uf8I5of/QG0/wD8BU/woA0qKzf+Ec0P/oDaf/4Cp/hR/wAI5of/AEBtP/8AAVP8KANKis3/AIRzQ/8AoDaf/wCAqf4Uf8I5of8A0BtP/wDAVP8ACgDSorN/4RzQ/wDoDaf/AOAqf4Uf8I5of/QG0/8A8BU/woA0qKzf+Ec0P/oDaf8A+Aqf4Uf8I5of/QG0/wD8BU/woA0qKzf+Ec0P/oDaf/4Cp/hR/wAI5of/AEBtP/8AAVP8KANKis3/AIRzQ/8AoDaf/wCAqf4Uf8I5of8A0BtP/wDAVP8ACgDSorN/4RzQ/wDoDaf/AOAqf4Uf8I5of/QG0/8A8BU/woA0qKzf+Ec0P/oDaf8A+Aqf4Uf8I5of/QG0/wD8BU/woA0qKzf+Ec0P/oDaf/4Cp/hR/wAI5of/AEBtP/8AAVP8KANKis3/AIRzQ/8AoDaf/wCAqf4Uf8I5of8A0BtP/wDAVP8ACgDSorN/4RzQ/wDoDaf/AOAqf4Uf8I5of/QG0/8A8BU/woA0qKzf+Ec0P/oDaf8A+Aqf4Uf8I5of/QG0/wD8BU/woA0qKzf+Ec0P/oDaf/4Cp/hR/wAI5of/AEBtP/8AAVP8KANKis3/AIRzQ/8AoDaf/wCAqf4Uf8I5of8A0BtP/wDAVP8ACgDSorN/4RzQ/wDoDaf/AOAqf4Uf8I5of/QG0/8A8BU/woA0qKzf+Ec0P/oDaf8A+Aqf4Uf8I5of/QG0/wD8BU/woA0qKzf+Ec0P/oDaf/4Cp/hR/wAI5of/AEBtP/8AAVP8KANKis3/AIRzQ/8AoDaf/wCAqf4Uf8I5of8A0BtP/wDAVP8ACgA1T/kI6N/1+t/6TzVpVQg0LSLW4juLbS7KGaMkpJHborISCDggZHBI+hNX6AP/2Q==" alt="" width="667" height="638" vspace="0" hspace="0" border="0" style="width:667px;height:638px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />After oral administration, metronidazole is rapidly absorbed, at least 80 % in one hour.<br />The plasma peaks obtained after oral administration are the same than those obtained after<br />intravenous administration of similar doses.<br />Bioavailability via oral route is 100 %. It is not significantly decreased by simultaneous<br />ingestion of food.<br />Diffusion<br />-about 1 hour after single dose of 500 mg, the mean maximal plasma concentration is 10<br />microgrammes/ml. After 3 hours, the mean plasma concentration is 13,5 microgrammes/ml<br />-Plasma half-life is 8 to 10 hours<br />-Blood protein-binding is less than 20 %<br />-The apparent distribution volume is important about 40 1 (i.e 0.65 l/kg)<br />-It is rapidly and extensively distributed with concentrations close to serum levels, in the<br />lungs, kidneys, liver, skin, bile, C.S.F., saliva., seminal fluid, vaginal secretions. It passes<br />through the placenta and into the mother&#39;s milk.<br />Biotransformation<br />The product is metabolized principally in the liver by oxidation. Two metabolites are formed:<br />- The principal &quot;alcohol&quot; metabolite, that has about 30% of the antibacterial activity of<br />metronidazole against anaerobic bacteria, and an elimination half-life of about<br />11 hours;<br />- The &quot;acid&quot; metabolite, present in lower quantities, that has about 5% of the<br />antibacterial activity of metronidazole.<br />Excretion<br />Strong hepatic and biliary concentration ; weak colic concentration ; weak faecal elimination.<br />Excretion is chiefly of urine as metronidazole and oxidized metabolites excreted in urine<br />represent about 35 to 65 per cent of the administered dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not aplicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not aplicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not aplicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                5 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30⁰C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not aplicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NOT REQUIRED</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                sanofi-aventis France
1-13, boulevard Romain Rolland
75014 Paris
France
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2003
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>